How Mitochondria Control Your Metabolism | Dr. Jared Rutter

Dr. Jared Rutter, PhD, Professor of Biochemistry at the University of Utah and Howard Hughes Medical Institute Investigator, is a leading expert on mitochondria and metabolism. He explains how mitochondria produce the energy for your cells to work but also how they regulate cell growth and replication and thereby contribute to health and disease. We also discuss how mitochondria are linked to aging, cancer, and other diseases. Our conversation explores your metabolism as the composite of trillions of individual cells and points to new ways to improve health, avoid, and treat diseases. Show notes: https://go.hubermanlab.com/297-jared-rutter Pre-order Protocols: https://protocolsbook.com Thank you to our sponsors AG1: https://drinkag1.com/huberman Joovv: https://joovv.com/huberman BetterHelp: https://betterhelp.com/huberman Eight Sleep: https://eightsleep.com/huberman Function: https://functionhealth.com/huberman Timestamps (00:00:00) Jared Rutter (00:02:29) Metabolism, Cells; Aging (00:08:36) Mitochondria, Origin & Cell Complexity (00:13:07) Sponsors: Joovv & BetterHelp (00:15:16) Mitochondria Genome, Inheritance (00:18:18) Mitochondria & Spatial Distribution; Cell-Specific Metabolism (00:25:59) Nutrient Energy, Hormones, Fat Cells (00:31:13) Glucose, ATP Conversion, Pyruvate (00:36:41) Cell Choice: Energy or Growth, Cancer; Virus (00:46:02) Sponsors: AG1 & Eight Sleep (00:48:36) Microbiome, Role of Humans (00:51:44) Molecule Discovery Process, MPC1, MPC2 (00:59:42) Cell Resource Sensing, Fasting, Glucagon, Fat Cells; Neurons, Heart (01:07:03) Cell Resource Allocation, MPC, Heart Failure; Disease (01:11:46) Sponsor: Function (01:13:24) Cell Size vs Fuel Balance, Cell Identity & Disease (01:20:43) MPC Discovery, Genetics, Model Systems (01:24:29) Lactate, Oxygen, Exercise; Energy Prioritization Hierarchy (01:31:32) Cancer, Mutations, Metabolism Changes & Warburg Effect (01:36:18) Cancer Challenges & Therapies (01:43:00) Therapy Combinations, Unique Cancer Mutations & Metabolism (01:48:31) Technology to Visualize Metabolism; Disease, Metabolism & Scents (01:56:34) Excess Energy & Mitochondria, Reactive Oxygen Species (02:01:12) Zero-Cost Support, YouTube, Spotify & Apple Follow, Reviews & Feedback, Sponsors, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

Speaker names marked ? are inferred from speaking time and the show’s known hosts — they are not voice-verified.

• 0:00Speaker 00

  There's a widely accepted hypothesis that mitochondria with excess energy leads to problems. Many people that are listening have probably heard of reactive oxygen species. This is forms of oxygen that become reactive and end up spinning out and damaging proteins and nucleic acids. And I think it is widely accepted that one of the contributors to that is mitochondria that have too much energy. Basically, the form that energy takes when it's extracted from the food we eat and before it's converted to ATP is powering the mitochondria. And when that mitochondria is overpowered, that leads to a state that is very susceptible

• 0:41Speaker 00

  to generation of these reactive species that end up damaging our genome, creating mutations and damaging proteins and creating many of the problems that we see.

• 0:51Andrew D. Huberman?

  Welcome to the Huberman Lab Podcast, where we discuss science and science-based tools for everyday life.

• 1:00Andrew D. Huberman?

  I'm Andrew Huberman, and I'm a professor of neurobiology and ophthalmology at Stanford School of Medicine. My guest today is Dr. Jared Rutter. Dr. Jared Rutter is a professor of biochemistry at University of Utah and an investigator with the Howard Hughes Medical Institute. He is one of the world's top experts in the biology of mitochondria and metabolism. Mitochondria are known as the powerhouse of the cell, but as you'll learn today, they do far more than just power our cells. They also determine how much energy goes into making new cells, to making sure that cells stay healthy, and to fighting off disease. Today's conversation explains how mitochondria do that and clarifies what your metabolism really

• 1:42Andrew D. Huberman?

  is. And in doing so, you will learn that you don't have one metabolism. Your metabolism, as it's called, is actually a reflection of the constellation of all the metabolisms of all the cells in your body. So today's conversation will teach you the real biology of mitochondria, and it will provide a framework for you to make better decisions on the behalf of your health. So what follows is a conversation about mitochondria and metabolism unlike any that you've heard from one of the world's premier experts in this topic. Before we begin, I'd like to emphasize that this podcast is separate from my teaching and research roles at Stanford. It is, however, part of my desire and effort to bring zero cost to consumer information about science and science-related tools to the general public. In keeping with that theme, today's episode does include sponsors. And now for my discussion

• 2:27Andrew D. Huberman?

  with Dr. Jared Rutter. Dr. Jared Rutter, welcome.

• 2:31Speaker 00

  Thank you. Thanks for having me on.

• 2:32Andrew D. Huberman?

  I have many questions about metabolism, mitochondria, and I know many people do as well. Most people hear the word metabolism, and they think calories in, calories out. They hear the word mitochondria, and they probably think the powerhouse of the cell. And that's all great. People are becoming more educated about cells and their bits and pieces and what they do. You have a very different perspective that is very important, I believe, for people to understand. Maybe we could start off by talking about how the metabolism of any one cell in our body relates to what we call our metabolism, the collective metabolism of all those cells. And as you go, if you could take any liberties you want

• 3:14Andrew D. Huberman?

  to tell us what we probably don't know about the quote-unquote "powerhouses" of the cell.

• 3:20Speaker 00

  You know, when we think about metabolism, as you say, I think all of us think about metabolism in terms of our body's metabolism, our metabolic rate, as you say, calories in, calories out. What that is really, our body's metabolism is basically the sum total of what we ingest, you know, what we eat, what we drink, what we breathe. That enters our body and gets processed. And the results of that processing are individual molecules, amino acids, and sugars, and so forth, that then distribute throughout the body, go into individual cells, and enter this process that we call metabolism, or we call cellular

• 4:00Speaker 00

  metabolism. And I think it's reasonable to think of cellular metabolism as almost like a map. There's an entry point, a molecule of glucose, a sugar, comes into a cell, and that sugar can be chemically modified in a variety of ways to fulfill the needs of that cell. And then that cell does whatever it needs to do with the molecules it takes in to fulfill its particular functions. And then that leads to the release of waste products that we eliminate from our body. And that is sort of the organismal metabolism, the metabolism of our body. And as you allude to, I think something that maybe many people

• 4:42Speaker 00

  don't understand is that cellular piece of it. The metabolism of our body is really the sum total of the metabolism of each one of our 30 trillion cells or so. That's really where my passions lie, are those individual cells and how they choose to take up certain nutrients, how they choose how to process them, turn them into other things, how they use them to fulfill their particular functions, and how that's regulated. The masterful coordination of each of those cells working together to allow us to be sitting here, talking to one

• 5:23Speaker 00

  another, and go out and run, or whatever we do. It's a beautiful orchestration, but that happens at the level of individual cells. And I think that's one of the fascinating things that is maybe a little bit less understood.

• 5:36Andrew D. Huberman?

  If we were to just take the single-cell view for a moment, and I know that aging isn't like your specific area of interest, but one thing that's always intrigued me because my postdoc advisor once came down the hall and said, "Why do I have so much less energy than I used to?" And he had a ton of energy, so that I was like, "I wonder what it used to be like." But it's a great question. He used to do this every once in a while, like just ask these very basic questions that no one else on our halls at Stanford could really answer. Why does a kid have so much energy, and when we're older, we don't? What people say, "Well, people are moving less. The tissues are wearing out." But at the level of energy production, are we aware, as biologists at this point in

• 6:16Andrew D. Huberman?

  history, as to why a young cell, it could be muscle cell, it could be neuron, whatever, versus an older version of that cell, why it either produces less energy, I don't know if it does, I'm guessing it might, but why the whole body just seems to have less get-up-and-go? Do we have an answer for that?

• 6:36Speaker 00

  I think we have a partial answer for that. I think that's definitely a frontier of science, is trying to understand exactly what goes wrong during aging. There's many aspects to it. As you alluded to, one of my passions also is the mitochondria, and I think it's almost universally the case that mitochondria become less energized, less effective, let's say, as we age. And the reasons for that are, to some extent, clear, but I think largely unclear. But that is definitely a feature of the aging process. You know, there is this sort of aspect of accumulation of damage. You know, living in the world we

• 7:17Speaker 00

  live in, as I alluded to before, this orchestration of metabolism that happens throughout the body, that's hard. It's expensive. And it's expensive not only in terms of what we need to eat to fuel it, but it's expensive in terms of the damage that can come as a side effect of that. And the accumulation of that damage over time is certainly correlated strongly with aging. And I think there's some really nice evidence in models where we can do genetics, you know, in animal models, that suggests that that accumulation of damage is a big part of the aging process. And it's a huge area of interest in the field is trying to understand how you can decrease the onset of damage, how you can reverse damage

• 8:00Speaker 00

  that comes. One thing that I like about how you ask that question is thinking about that in the context of the cell, which, again, I don't think we tend to think of aging as a cellular phenomenon, but I think fundamentally, it almost has to be. We are made up of cells, and the processes that lead to aging are the accumulation of processes that happen at the level of individual cells. And I think in a way, we're at the precipice of understanding a lot of this because of the tools that we are starting to have access to that will help us better understand cause and effect and the specific molecular features of the aging process.

• 8:36Andrew D. Huberman?

  Let's talk about mitochondria. Perhaps surprisingly, I'm going to ask you why you study them, with the caveat that they are incredibly interesting. They are involved in energy production and metabolism. But what specifically drew you to mitochondria versus all the other pieces of cells or parts of the body or organs that you could have worked on? Why the mitochondria? What's so sticky about those as a place to, I mean, you devote a significant fraction of your life to them?

• 9:04Speaker 00

  Yeah. It's an area of cell biology, an area of sort of the details of how life works. One of these things that is, in my view, just a brilliant example of taking chemistry of incredible complexity and making it work effectively inside of a living cell. Mitochondria are believed to have been the result of an endosymbiotic event where a bacterium, a free-living bacterium...

• 9:35Speaker 00

  Was engulfed by another cell and in a way kind of domesticated.

• 9:42Andrew D. Huberman?

  So why to think about?

• 9:43Speaker 00

  Totally wild.

• 9:44Andrew D. Huberman?

  I'm sure people are following, but in case there's somebody who's not. What Jared is saying is that our cells basically were invaded by a bacterium. And then that bacterium became part of our stable genome going forward. Went into the, what we call the germ line and therefore was propagated from parents to kids. And so now mitochondria live in us, but they didn't start off living in us.

• 10:09Speaker 00

  That's right.

• 10:10Andrew D. Huberman?

  And, and we hear that about the gut microbiome, like we have these trillions of bacteria that live in us and we colonize and we can recolonize. Take antibiotics, then you need to replenish, eat your yogurt and so on. But, but the fact that the mitochondria made it stably into our genome and are transmitted from one generation to the next. We think of them as us, but you're saying there is solid evidence that they came from outside of humans.

• 10:32Speaker 00

  I think that's the only model that I think any of us as scientists have any good reason to believe. And, you know, that's fascinating history, right? That there was a bacteria in another cell that got together and, and together that combination could do things that, that any one of either of them on their own could not do. And that they work together in, in some way to enable the evolution of complex life. You know, eukaryotes, which are the, the type of cell that resulted from that combined situation that we were just talking about. These are all the organisms that we see around us, plants, animals, fungi even,

• 11:15Speaker 00

  are all the result of these two cells getting together and making peace, so to speak. And, uh, teaming up to make this synergistic cell.

• 11:24Andrew D. Huberman?

  Is it synergistic? For, forgive me for interrupting, but when I think about viruses, I think viruses have their own sort of intelligence. They kind of, they hijack the genomes of cells and they either kill those cells or if they're really smart. They keep them, those cells alive and use those cells to continue to live and then propagate through like the behavior of an animal, like the rabies virus. Like, oh, let's get this animal aggressive so that it bites. And then, I mean, viruses don't think, but they have an intelligence. Do we know that the mitochondria were benefiting the cells and the cells were benefiting the mitochondria? Or could have this been a takeover by, by the mitochondria?

• 11:58Speaker 00

  I mean, this is a, a bit of a philosophical question. Of course, we don't have a record of, of what exactly happened, when and who benefited in real time. But one thing we do know is all of complex life resulted from cells that underwent that event, one time or multiple times, but all of complex life evolved from that. And I think that tells us that more than likely, complex life could not result from a bacterium on its own or the archaea, the, the, the cell that became the host for that bacteria. So I think you can make a compelling argument that this was beneficial. And one reason it was beneficial, because it enabled a form of metabolism that wasn't possible before.

• 12:44Speaker 00

  And enabled now a more complex cell to be able to do things metabolically, to be more metabolically efficient and, and diversified. That it could enable, you know, again, complex life to evolve and totally fascinating history. But I think, as you alluded to, also has very interesting implications for life today.

• 13:07Andrew D. Huberman?

  I would like to take a quick break and acknowledge one of our sponsors, JOV. JOV makes medical grade red light therapy devices. Now, if there's one thing that I have consistently emphasized on this podcast is the incredible impact that light can have on our biology and our health. Now, in addition to sunlight, which I've talked about a lot on this podcast, red light, near infrared and infrared light have been specifically shown to have positive effects on improving numerous aspects of cellular and organ health. These include faster muscle recovery, improved skin health, wound healing, improvements in acne, reduce pain and inflammation, improve mitochondrial function, and even improvements in vision. Nowadays, there are a lot of red light devices out there.

• 13:48Andrew D. Huberman?

  But what sets JOV lights apart and why they're my preferred red light therapy device is that they use clinically proven wavelengths, meaning they use the specific wavelengths of red light, near infrared and infrared light in combination to trigger the optimal cellular adaptations. Personally, I use the JOV whole body panel about three to four times a week, usually for about 10 to 20 minutes per session. And I use the JOV handheld light both at home and when I travel. If you would like to try JOV, they're offering up to $400 off select products for listeners of this podcast. To learn more, visit JOV, spelled J O O V V dot com slash Huberman. Again, that's J O O V V dot com slash Huberman. Today's episode is also brought to us by BetterHelp.

• 14:31Andrew D. Huberman?

  BetterHelp offers professional therapy with a licensed therapist carried out entirely online. I've been doing therapy for a long time. And while it's not always easy, every time I do a therapy session, I come away feeling better and knowing that the time was well spent. With BetterHelp, they make it extremely easy to find an expert therapist who can help provide the benefits that come through effective therapy. And the data say it works. BetterHelp has an average rating of 4.9 out of 5 for its live sessions, based on over 1.7 million client reviews. Also, because BetterHelp is done entirely online, it's extremely time efficient. If you would like to try BetterHelp, go to betterhelp.com/huberman to get 10% off your first month. Again, that's betterhelp.com/huberman.

• 15:16Andrew D. Huberman?

  Could we explore a little bit of how mitochondria getting into these cells were able to make it stably into their genome and propagate? This isn't going to be a conversation about genetics per se, but I may, maybe as a just two points of background for people. Like if any of our cells have something put into them, but let's say a physical object, like a splinter, little tiny piece of splinter stays in the cell and then you procreate with somebody. You don't expect that child will have that.

• 15:41Speaker 00

  Yeah.

• 15:41Andrew D. Huberman?

  Little bits of splinter in their cells. But if the germ line, right? So the, the eggs or the sperm have something incorporated into them, then potentially it could propagate. That's why they call germ line as opposed to somatic cells. I, I think most people aren't aware of that. It makes perfect sense. Once you hear it. But you're talking about many, many, many years ago, a cell having this bacterium go into it. And then it was somehow able to stably represent itself in the genome so that that propagated forward. And eventually it has to be in the germ line of whatever, you know, primordial homo sapiens were there. Otherwise your kid's eye, you wouldn't have mitochondria in us. How do we think that might've happened?

• 16:23Speaker 00

  The main genome of the cell, the cellular genome, DNA contained typically in the nucleus of the cell. Mitochondria exist in the cytosol outside the nucleus. One of the interesting things about mitochondria, which I think is totally fascinating and has really interesting disease implications and worthy of talking about, we may or may not come back to it, is that mitochondria have their own separate genome that is sort of a relic of the bacterium that they are the descendants of. It's in a circle like the bacterial genomes, whereas the nuclear genome of a eukaryotic cell is linear chromosomes.

• 17:02Speaker 00

  And that genome performs very essential functions and codes very important proteins that enable our mitochondria to function as the powerhouse of the cell, which we know them to be, to enable the extraction of usable energy from the food that we eat. So as you alluded to, those cytoplasmic mitochondria somehow make it from generation to generation. And one of the interesting features of them being cytoplasmic is they're completely inherited from the mom, from the egg. Cause as you know, when the sperm invades the egg, the, the genome from the sperm gets into the, the egg, fertilizes it. The cytoplasm of the sperm does not.

• 17:46Speaker 00

  So the mitochondrial genome of you came completely from your mother. Mine came completely from my mother. And again, that has interesting implications for the inheritance of diseases that are mitochondrial in origin. But that's sort of how we think it works. It basically propagates from the egg upon fertilization. Then it gets distributed to all the cells, including the, the germ line that that fertilized embryo will have. And then gets passed on to the next generation in the same way.

• 18:18Andrew D. Huberman?

  Ratcheting toward the actual functioning of mitochondria, maybe you gave a beautiful picture of the mitochondria not in the nucleus of the cell, but in the cytoplasm, so still inside the cell. And most people probably remember from their high school biology, a picture of a cell always looks round. I'm guessing you're going to tell us that the mitochondria can be distributed lots of places in the cell. Cause a lot of cells aren't round. A lot of them look hairy or they have long extensions like neurons. Is it fair to say that you can find mitochondria everywhere in a cell? So no matter what shape it is, it's got mitochondria everywhere. And if so, what is the importance of having mitochondria distributed spatially through the cell? So maybe we go, so that people know where we're going, we'll, we'll talk about the spatial distribution because it turns out that's very important.

• 19:03Andrew D. Huberman?

  We'll talk about the functioning and then I want to talk about time as a factor. And that can be a little bit abstract for people who come to that.

• 19:09Speaker 00

  Yeah, spatially, you know, I, I, one of my scientist colleagues might call me on this, but to my knowledge, I can't think of a place that exists in cells where there aren't mitochondria. And I think as you alluded to, I, it's a little bit dangerous for me to talk about neurons with a neuroscientist. I am not a neuroscientist, but one of the brilliant bodies of work that's been done on mitochondria has been done in neurons. It's fascinating, these, these neurons that have one meter long projections and mitochondria transit from the cell body down those projections. And as best we can tell, those mitochondria play essential roles at the ends of those projections,

• 19:52Speaker 00

  typically being able to generate, again, usable energy. They're extracting the energy from the food that we eat, empowering the neurotransmission, the, the functions of those nerve, nerve terminals. And I think that's true of virtually every cell in our body. The extraction of energy and turning it into a usable form, typically in the form of ATP, adenosine triphosphate. Obviously that is the energy currency that's used by almost every cell in our body. And that is a key function of mitochondria. We'll probably come to functions of mitochondria that are outside of just extracting energy. But that is a critical function of mitochondria and that ATP is needed in virtually every place of every cell.

• 20:37Speaker 00

  And by having local production, that makes it more efficient. So I think spatial distribution is a key part of that. It's fascinating. There's been beautiful work that's shown that when a cell is crawling, a cell sometimes do, you know, like an immune cell that sees something it's chasing.

• 20:55Speaker 00

  There will be a distribution of mitochondria towards that leading edge of the cell, which is very energetically expensive to crawl for a cell. It requires a lot of ATP. And mitochondria will congregate at that leading edge where that ATP is being consumed to make ATP right there so it can be used. I think it's a fascinating example of that local demand for energy.

• 21:19Andrew D. Huberman?

  I'm asking some high level questions, I realize, but is there any reason to believe that a given mitochondria knows what cell it belongs to? Like, are they different? Is the mitochondria in one cell type so very different than the mitochondria in another cell type? And are the mitochondria between, like, let's say, a neuron of the eye? Or, let's get out of, since you're saying you don't want to talk neurons, as a per se. Like, is, you know, two adjacent skin cells, they're both skin cells, they have mitochondria in them, but do they know which cell they belong to? And do your mitochondria, I'm guessing because they came from your mom's genome, they know that they're different than my mitochondria, but how much identity do they have?

• 22:00Speaker 00

  Yeah. I would say this is a topic that is at the frontier of what we know. You're asking some questions that are right at the edge of our current knowledge. Yeah, mitochondria are different. To a first approximation, you could say that virtually every cell in our body has slightly different mitochondria that are particularly suited to the demands of that cell. A heart muscle cell, a cardiomyocyte. That cell kind of has one job, and that's to contract every second of every minute of every hour of every day for our entire life. And when it coordinates that contraction with the other cells in the heart, that enables our heart to beat. That's what its job is.

• 22:43Andrew D. Huberman?

  Is there any turnover of those cells? We know neurons don't tend to turn over.

• 22:46Speaker 00

  Very little, very little.

• 22:47Andrew D. Huberman?

  Well, that's reassuring.

• 22:48Speaker 00

  Very, very little.

• 22:50Andrew D. Huberman?

  I'm glad to hear that.

• 22:51Speaker 00

  You can imagine that it would be hard to replace that in real time, right? That's a, I'm a hockey fan, and that's a change on the fly scenario of biblical proportions. So that, those cardiomyocytes, their mitochondria is wired to consume whatever it has available and make ATP, because that ATP is going to be incredibly important to enable that contraction of that cell and the beating of the heart. Mitochondria in other cells, for example, like cells that line, that are the stem cells that enable our intestinal lining to be turned over every five to seven days, which is amazing, by the way.

• 23:31Andrew D. Huberman?

  Your whole gut.

• 23:32Speaker 00

  Your whole gut is turning over every five to seven days. The lining of that, of your gut, it is, it is amazing. Those stem cells, ATP is not the major demand of those, of those cells. They need to completely duplicate themselves constantly, every day or less. So their metabolic program is very different from a cardiomyocyte, which just needs to make ATP to a first approximation. They need to make a whole new cell. So we talked about, you know, the metabolism of the organism. The metabolism of those cells is very complex because it needs to replicate all the DNA,

• 24:14Speaker 00

  duplicate it to go into a new cell, duplicate all the proteins, duplicate all the membranes, the lipids, and that needs to happen rapidly. And so that metabolic wiring is completely different. And again, the mitochondria are fundamental to that. So those mitochondria are wired in a way that enable them to produce the biomass that's required to make a new cell, quite different from the mitochondria of a cardiomyocyte. And that distinction plays out in virtually all cells in our body, right? Every one of our cells has some particular purpose, some particular function that it serves for the body.

• 24:55Speaker 00

  And the demands of the mitochondria, therefore, of that cell are different, depending on the unique functions and demands of that cell. And so it's a fascinating topic, this diversification of mitochondria. I think, again, that's something that we're learning about. One of the developments that's really been happening over the last few years, very much a frontier field, is you might imagine a cell that has a complex set of demands. There's actually evidence, most prominently published recently by Craig Thompson at Sloan Kettering, that showed that in one cell, you can have two different kinds of mitochondria that have two different functions, and they're distinct in one cell.

• 25:37Andrew D. Huberman?

  What, what's each of them doing?

• 25:39Speaker 00

  Yeah, one of them tends to be more biosynthetic, maybe producing biomass, and one of them tends to be more energy extracting and producing ATP. That's an overly simplified, but generally accurate way of thinking about it. It really emphasizes this unique function of mitochondria that can be adapted, again, for the needs of the cell.

• 25:59Andrew D. Huberman?

  Okay, so I eat some food, and that food's absorbed, and I get glucose circulating in my bloodstream, I've got some stored energy in the form of glycogen, et cetera. And I'm curious, how greedy are the different mitochondria? Is the name of the game that every cell is trying to get as much energy as it can to produce as much ATP as possible? Or are they communicating, and is energy being allocated in some way that's a little bit more democratic?

• 26:25Speaker 00

  Yeah.

• 26:25Andrew D. Huberman?

  That's one question. And then framed within that, I could imagine two scenarios. One, non mutually exclusive, where like the vasculature just distributes the glucose very well to everything, so everybody, every cell gets, gets access to some of this glucose, and, and then is just greedily trying to make as much ATP as possible, and the whole system works beautifully. I could also imagine a situation where there's some shuttling to important structures like the brain, you know, that like keep you alive, like breathing, heart, there's a prioritization of organs. I'm talking about under non-stressful conditions. So, yes, how is energy allocated to cells? And then how are cells divvying up the goods?

• 27:03Speaker 00

  Yeah. It's a brilliant question and a fascinating area of physiology. As you allude to, when we eat, our digestive system starts extracting the constituents of what we eat, again, sugars, amino acids, fats, from that food. That then triggers signals of different kinds, GLP-1 being one, insulin being another. Those signals then are hormones. They get secreted, and they go to many cells throughout the body. And that tells each individual cell, we just ate. And the implications of that are different from each cell. Some cells don't care. Some cells don't pay attention to that, and they just keep on doing what they were doing. Some cells care a lot.

• 27:47Speaker 00

  Adipocytes, for example, these are the fat cells, the cells that make up our fat tissue. They care a great deal about that. And when they see insulin, what they do is they turn on a protein, they start making a protein that will cause glucose to be taken up into that adipocyte, that fat cell. And that glucose will then be converted through a series of chemical reactions into a fat molecule. And then that fat molecule will be stored away in a way that is very safe and enabled to be stored for potentially a very long time. And again, it's a beautiful way for the organism to coordinate, I just ate.

• 28:32Speaker 00

  Our energy status as an organism, as a body, is great, it's very good. So let's squirrel away some of that energy in the form of fat that can be stored in our adipocytes, again, very safely, and can be then used when we go through a period of prolonged fasting, which doesn't happen for us all that frequently, but happened for our ancestors probably much more frequently. And those adipocytes, full of fat, from when we ate, probably kept our ancestors alive when they went through the periods of prolonged fasting. Insulin has other effects on muscle and other cells throughout the body that, again, this is the brilliance of this coordination.

• 29:16Speaker 00

  The response of different cells to the fed state is different depending on the, the needs and functions of that cell. Again, some cells don't care at all, they're going to just go about and do their business. And some cells completely rewire their function depending on the metabolic state, the fed, fasted state of the organism.

• 29:38Andrew D. Huberman?

  So the picture you just described leads me to conclude that basically every cell obviously knows its job and is not greedily, but is diligently fulfilling that role.

• 29:51Speaker 00

  Yeah.

• 29:51Andrew D. Huberman?

  And somehow, the whole thing is orchestrated so that, like, we work. Which I know, I think for some people it might be like, duh, but just like, think about that.

• 30:01Speaker 00

  It's crazy.

• 30:01Andrew D. Huberman?

  Like, the liver cell isn't really talking to the brain cell in any kind of direct way about how much glucose it has access to. What you described makes me really understand for the first time the brilliance of having this hormone signal insulin, not just as a shuttle, because I think most people, we think of like insulin sensitive, most people who listen to this podcast are just existed in the world today, they're like, oh, you want to be insulin sensitive, you want your cells to recognize this signal. But we've never actually talked on this podcast about what exactly that signal is. We think about insulin as a shuttle.

• 30:29Speaker 00

  Yeah.

• 30:29Andrew D. Huberman?

  But the size of that signal is saying what's likely to be there. And I realize has all sorts of cool implications. I can prepare the cell to like, oh, I'm going to go to work hard now to be the little squirrel that I am over fat cell, and like squirrel away as much as I can, or be a brain cell, it's like, let's go, I'm ready to fire action potentials if I need to.

• 30:49Speaker 00

  Yeah.

• 30:49Andrew D. Huberman?

  And some cells, like the photoreceptors in the eye, are just doing that.

• 30:52Speaker 00

  Yeah.

• 30:52Andrew D. Huberman?

  Eyes closed, they're firing, eyes open, well, it's tricky, but they're more or less firing, it's not worth going into, obviously. But in every one of these cells, mitochondria are the ones that are essentially going to drive this ATP thing, right? And that seems extremely efficient, too, to just have essentially one major cellular energy source. So if you could walk us through what happens as glucose gets into the cell, and really what we've not done ever on this podcast, and I don't think I've heard elsewhere on any podcasts, maybe it's out there, but is how you go from ATP to actually the cell being able to perform its roles? And I realize there's a lot of biochemistry there, but you've worked on some really linchpin

• 31:36Andrew D. Huberman?

  molecules in that pathway that perform very specific roles, and so like, maybe we could really talk about what basically gets us from ATP to pyruvate, which might scare some people away, but you'll educate us as to why it's not scary, it's just super cool, and why it's so important to have these signals that, that aren't just like chemicals, they actually mean something for the cell. Because for me, forgive me for going a little long here, but then I'll shut up. I think if people can really internalize this idea that, yeah, like hormones go up, hormones go down, cortisol goes up with stress, it goes down, you wake up, cortisol goes up, melatonin when you're sleepy. It's not just that it's there. But that the size of the signal says a lot more than just be sleepy. It's saying what once happened is different than what's happening now.

• 32:20Andrew D. Huberman?

  It sets a stage for what happens next. And this is really like the verbs of biology that are harder to communicate, even in video.

• 32:27Speaker 00

  Yeah.

• 32:27Andrew D. Huberman?

  So take us from glucose to ATP and ATP to this thing that we call energy.

• 32:34Speaker 00

  Yeah, there's obviously a lot to unpack there. Glucose is the dominant, let's say carbohydrate, the dominant sugar that most of our cells are consuming. And when glucose is brought into a cell, it goes through, again, a series of chemical reactions that we call glycolysis. And I'm going to simplify because there's obviously

• 32:55Andrew D. Huberman?

  Sure.

• 32:55Speaker 00

  This is the subway map of New York. There's a lot of branches going all over the place that we're gonna

• 33:00Andrew D. Huberman?

  We just need to go north.

• 33:01Speaker 00

  Yeah. North and south.

• 33:03Andrew D. Huberman?

  Which is pretty much the only direction you can go on the cell. I'm not in New York, I'm kidding. I realize you can go across the, across the, yeah.

• 33:08Speaker 00

  Yeah, don't insult the New Yorkers.

• 33:10Andrew D. Huberman?

  Yeah.

• 33:10Speaker 00

  So glucose comes into a cell, goes through a series of chemical reactions. And you mentioned it gets to pyruvate. That's the endpoint of glycolysis, this set of chemical reactions. And then pyruvate, there's a decision that has to be made by that cell. It can either

• 33:29Speaker 00

  take that pyruvate into the mitochondria and burn it essentially, oxidize it, which is essentially burning it, combining it with oxygen. And that is a very effective way to extract all the energy that can be extracted from that glucose via pyruvate.

• 33:46Andrew D. Huberman?

  Tell us a little bit about pyruvate.

• 33:48Speaker 00

  Yeah.

• 33:48Andrew D. Huberman?

  What's the best way to like conceptualize pyruvate for, for somebody like me?

• 33:53Speaker 00

  It's an intermediate. It's a midpoint, let's say, from glucose. Glucose is a six carbon molecule, a complex chemical, six carbon chemical. That gets, again, chemically modified down to this pyruvate, which is, as I alluded to, in a way, kind of a pivot point in the metabolism of that glucose. And the reason why we became really fascinated with pyruvate is because of that bifurcation that happens. Pyruvate can either be, again, taken into mitochondria and burned. And that's very effective for generating ATP, for extracting all the energy that can be extracted. And that's what cardiomyocytes, for example, really love to do.

• 34:36Speaker 00

  Take that, everything they can from the circulation, burn it, make ATP, keep our heart pumping. And again, other cells, on the other hand, don't do that. They don't need as much ATP. So those intestinal stem cells that I talked about that are the factory in a way that's enabling the repopulation of our gut lining every week. They do something different with that pyruvate. They, instead of burning it, turn that pyruvate and other molecules, intermediates in glycolysis, into biomass, into the stuff that will enable that one cell to duplicate itself. And I've become totally fascinated with this bifurcation.

• 35:19Speaker 00

  Food can either be converted to energy or it can be converted to biomass. I think that's maybe a bit overly simplistic, but I think a good baseline way to think about the, what we get out of the food that we eat. Energy or building blocks that can be used to make a new cell, to repair a cell that's been damaged, for a B cell, an immune cell, that are the ones that make antibodies. Making a bunch of antibodies, which an activated B cell needs to do, that's a lot of stuff that needs to be made. That requires that B cell to have a lot of amino acids that can be turned into proteins, which are, antibodies are proteins.

• 36:01Speaker 00

  And, and that, again, that's a very important part of our immune system that keeps us protected from invaders that might otherwise kill us. And so that, that distinction that lands at the point of pyruvate, I think is a, is a super fascinating pivot point in metabolism that I think many of us are fascinated by exactly how the cell organizes itself to make the right resource allocation decisions. You know, every one of our cells is all, every second of every day is making resource allocation decisions. What does it do with the stuff that it has? And, and this is one that I think is really fascinating.

• 36:41Andrew D. Huberman?

  So we are probably like seven, I'm insulting the cell biologists, but probably seven steps away from sandwich. So sandwich goes in the mouth, into the gut, gets absorbed, right? We get glucose, glucose gets into the cell. We've got some important biochemistry that, you know, is in this ATP generation pathway. And we get to this like key node that you're describing as pyruvate. And pyruvate is either gonna say, let's make more, you called it biomass, but stuff of cells.

• 37:08Speaker 00

  Yeah.

• 37:09Andrew D. Huberman?

  Sort of like you have lumber arriving, maybe, might be a decent enough analogy. You're either gonna use it to build more house or you're gonna burn it for heat energy.

• 37:17Speaker 00

  Great analogy.

• 37:18Andrew D. Huberman?

  Um, and let's look, make a, add a condition where you need to burn some of that lumber for heat energy to keep the construction project going.

• 37:26Speaker 00

  Exactly.

• 37:27Andrew D. Huberman?

  Okay. So at this key bifurcation, this key split point, is it just as metabolically demanding for a cell to use pyruvate to keep itself going, like a cardiomyocyte, versus making biomass, or is one more costly? I'm thinking, again, as you beautifully pointed out at the beginning, about thinking about that our metabolism as a whole body, as a person, is, is the sum total of all these, these things. Is it equivalent in terms of like, how much sandwich, relatively speaking, is going into maintaining us and rebuilding us?

• 38:00Speaker 00

  Yeah.

• 38:00Andrew D. Huberman?

  What you call biomass, what I'm calling building, you know, allocating lumber for the, for the house itself versus to fuel the fire, so to speak.

• 38:09Speaker 00

  That's hard math to do. There's a lot of nuance.

• 38:12Andrew D. Huberman?

  Rough percentages. I won't hold you to it.

• 38:14Speaker 00

  Yeah, no, I mean, one way to think about that, many of us are probably unfortunately aware of PET imaging, right? This is, this is something that happens, it's often used to diagnose cancer.

• 38:23Andrew D. Huberman?

  Positron emission tomography.

• 38:24Speaker 00

  Positron emission tomography. And FDG PET, which is the most common form of PET, is basically you're giving cells a form of glucose that can then be visualized with this PET scan that many people are aware of. And the reason we do that is because tumors take up a lot of glucose. An FDG PET is fluorodioxyglucose. This is a, a labeled version of glucose. So the reason we do FDG PET is to see the cells, where in the body is taking up a lot of glucose? And tumors take up a lot of glucose. So FDG PET is used to diagnose cancer frequently, very effectively. So that is one metric for this.

• 39:09Speaker 00

  A cancer cell is, again, a cell that is making a resource allocation decision all the time. But in the context of, of that cell, when it transforms into a cancer cell, that resource allocation becomes very much about building more cells. That's why a tumor is a tumor is because that one cell that was the first bad actor decided, instead of doing the thing it was supposed to be doing, decided to duplicate itself and duplicate itself again and build a cluster of cells that then become a tumor.

• 39:41Andrew D. Huberman?

  Okay, I have a pseudo philosophical question, but it's really a scientific medical question about tumors. Bacteria have the opportunity to hijack genomes of cells, viruses certainly. Probably the easiest example for people to understand is like a herpes virus, like HSV1 or something, which lives on neurons, doesn't kill the neuron, which is convenient for the virus.

• 40:04Speaker 00

  Right.

• 40:04Andrew D. Huberman?

  Right? Because if it killed the neuron, it too would die. Because the neuron is expressing that virus.

• 40:10Speaker 00

  Yeah.

• 40:10Andrew D. Huberman?

  It's the hijack the genome. So those earlier were saying like viruses have their own quote unquote intelligence.

• 40:15Speaker 00

  Yeah.

• 40:16Andrew D. Huberman?

  Like stay alive, but keep the host alive too and transmit. And in the case of rabies, it's like the most easy, it's one to conceptualize. Like impact areas of the brain that trigger aggression with it, trigger

• 40:27Speaker 00

  Right.

• 40:28Andrew D. Huberman?

  biting.

• 40:28Speaker 00

  Yeah.

• 40:29Andrew D. Huberman?

  And, and people have speculated, like, does the virus know that it's doing this? Like, probably not, right? Doesn't, they're not brains. But pretty impressive level of quote unquote adaptive behavior and intelligence.

• 40:40Speaker 00

  Yeah.

• 40:41Andrew D. Huberman?

  I think of cancer as just a bad thing all around, right? That these cells are greedy, they're taking glucose, they're making more of themselves. It's cell turnover gone awry. Tumor gets big, it starts to encroach on other tissues, metastasize, boom, you kill the host.

• 40:56Speaker 00

  Yeah.

• 40:56Andrew D. Huberman?

  That's not a great strategy from the perspective of the tumor.

• 40:59Speaker 00

  Yeah.

• 40:59Andrew D. Huberman?

  So it obviously isn't thinking about its long-term outcome in any kind of adaptive way. But has anyone ever looked at tumors in the same way that we think about viruses? Like, the logic there is the same.

• 41:10Speaker 00

  Yeah.

• 41:10Andrew D. Huberman?

  Except it, it seems that their goal is to kill the organism. I'm not trying to anthropomorphize about cells and cellular processes, but I think Is there a potential set of answers about how to deal with tumors? And think about cancer that could be borrowed from any of those other examples? Or am I going down the wrong path?

• 41:29Speaker 00

  Yeah, it's an interesting question. You know, viruses and bacteria, similar to how you were describing viruses. Some of the same principles apply to bacteria, parasitic bacteria. Viruses, as you allude to, their goal, if you do want to anthropomorphize them, their goal is to propagate, right? They are under evolutionary pressure. The way that that virus survives is to make more of itself, go infect another organism and have that other organism make a bunch of additional viruses that will then go and infect another organism, right? That is the evolutionary game. And that's what viruses do, and they're very good at it. And you described some really interesting biology where viruses will actually affect

• 42:13Speaker 00

  the behavior of the host to make them better at getting into the next host.

• 42:18Andrew D. Huberman?

  So wild.

• 42:18Speaker 00

  It's amazing.

• 42:19Andrew D. Huberman?

  I wish we had a better language for this thing because intelligence is not really it because it's not of brains. But it's this adaptive logic.

• 42:26Speaker 00

  Yeah, that's a good phrase for adaptive logic. That enables the survival and propagation of that virus. And this is how evolution works, of course. If that virus had a mutation that made it better able to do that, that virus then would infect better and it would get into hosts better, propagate better, and it would eventually take over the population of that virus. That is the process of evolution. And I think, again, it makes intuitive sense. You know, you asked about cancer. Cancer is obviously fundamentally different in one key way. If I get a virus and I come in here and we're sitting across the table and I'm hacking and whatever, and I spew across the table at you, you might get the virus,

• 43:10Speaker 00

  get sick, build a bunch of additional virus, and then you give it to coworkers. And that's viral propagation, which we all sadly know about. There's very little evidence that cancer is infectious.

• 43:23Andrew D. Huberman?

  What about the Tasmanian devils? I know about this.

• 43:26Speaker 00

  No, I don't know about this.

• 43:26Andrew D. Huberman?

  Okay, I don't know if this held up, but there was this idea for a while. Someone will tell us in the comments. This is what's fun about doing this on the internet. That Tasmanian devils fight and that there's wound-induced propagation of cancers. These very disturbing, as an animal lover, very disturbing images of these cute little animals with the little teeth there. They have a viciousness to them and they have these tumors growing at wound sites. And it turns out those are cancers. So there's somehow like fighting and wounds and it might be viral. It might be bacterial. I don't know. That's outside my expertise. But there was this idea that they could transmit cancers to one another through fighting.

• 44:05Speaker 00

  Interesting.

• 44:05Andrew D. Huberman?

  Which I thought was sad, but fascinating nonetheless. And Australia is a weird place.

• 44:11Speaker 00

  A lot of stuff happens.

• 44:12Andrew D. Huberman?

  I mean, the world's upside down down there. So after all, but right, you're right.

• 44:16Speaker 00

  In general.

• 44:17Andrew D. Huberman?

  Yeah, we don't actually think that people are catching cancers from one another.

• 44:22Speaker 00

  So when you think about the evolution of a cancer, the scope of that evolution is different, right? The scope of that evolution of a cell in me is limited to me. Cancer cells undergo evolution in the exact same way. You know, if one cell in my body starts propagating, it acquires a mutation that enables it to divide and divide faster. And maybe, you know, get out from underneath the limits that are being placed upon it by the immune system and by other systems that control propagation of cells in the body. It can then divide and divide again. And that's basically the continuous process of cancer development

• 45:02Speaker 00

  is the acquisition of mutations that make that cell better able to evade the immune system, to duplicate itself, evade the problems that would come with DNA damage, which many cancers have, and to continue to make cells that survive. And that is, in a way, an evolutionary process playing out at the level of individual cells. But how that interacts with the host is obviously different. Because, again, a virus has this sort of evolutionary drive to get from one organism to another to another to enable its propagation. Cancer isn't fueled by the same motivations, let's say.

• 45:46Speaker 00

  Because, again, as far as we're aware, that very rarely, if almost never, happens to get from one organism to another. And so the motivations are different, but the evolutionary process underlying it, it's the same principles that play in both.

• 46:02Andrew D. Huberman?

  I'd like to take a quick break and acknowledge our sponsor, AG1. AG1 just launched their newest formulation called AG1 Pro. And right now you can get an extra 20% off your first subscription. AG1 takes the clinically-backed AG1 formula, which is a blend of vitamins, minerals, probiotics, and adaptogens, and adds three important new ingredients: creatine monohydrate, calcium HMB, and zinc carnecine. It has five grams of creatine monohydrate to support muscle strength and performance along with brain health, calcium HMB to support muscle recovery and reduce muscle breakdown, and zinc carnecine to support and improve the lining of your gut. Some of these ingredients I personally was already taking, separate from the AG1 formula. So it's great to see all three of them now in the new AG1 Pro.

• 46:46Andrew D. Huberman?

  As you may know, I've been taking AG1 every single day for about 14 years now. That means I discovered it and started taking it daily long before I even knew what a podcast was. I continue to take it and back it here on the podcast because it is an excellent formula. And it's now even better with the AG1 Pro formula. For a limited time, you can get an extra 20% off your first subscription to AG1 Pro by going to drinkag1.com/huberman and using the code BACKTOROUTINE. So that's with a numeral two, back numeral two, routine. Just go to drinkag1.com/huberman. Today's episode is also brought to us by Eight Sleep. Eight Sleep makes smart mattress covers with cooling, heating, and sleep tracking capacity. One of the best ways to ensure you get a great night's sleep

• 47:29Andrew D. Huberman?

  is to make sure that the temperature of your sleeping environment is correct. And that's because in order to fall asleep and stay deeply asleep, your body temperature actually has to drop by about one to three degrees. And in order to wake up feeling refreshed and energized, your body temperature actually has to increase by about one to three degrees. Eight Sleep automatically regulates the temperature of your bed throughout the night according to your unique needs. I've been sleeping on an Eight Sleep mattress cover for nearly five years now, and it has completely transformed and improved the quality of my sleep. The latest Eight Sleep model is the Pod 5. This is what I'm now sleeping on, and I absolutely love it. It has so many incredible features. For instance, the Pod 5 has a feature called Autopilot, which is an AI engine that learns your sleep patterns

• 48:11Andrew D. Huberman?

  and then adjusts the temperature of your sleeping environment across different sleep stages. It'll even elevate your head if you're snoring, and it makes other shifts to optimize your sleep. If you'd like to try Eight Sleep, go to eightsleep.com/huberman to get up to $350 off the new Pod 5. Eight Sleep ships to many countries worldwide, including Mexico and the UAE. Again, that's eightsleep.com/huberman to save up to $350. I'll take us down one more estuary, then we are actually going to talk about mitochondria and pyruvate again, and your contributions to this critical node of where pyruvate puts its efforts, building more stuff of the cell or using energy. Anytime I have a serious cell biologist, which isn't that often on this podcast,

• 48:53Andrew D. Huberman?

  or somebody who thinks about the pieces that make up us, I try and ask this. I'm bothered by this one thing I heard once, which is that like it's so easy to think about evolution. It's like, okay, we're all adaptively trying to make more of ourselves, care for our young and go forward. That's like what every, most every mammalian species does. That all makes sense until I learned about the gut microbiome from my colleague, Justin Sonnenberg. And he said, you know, every time you shake hands, like we exchanged microbiome today. And we're sharing in the air and skin, we shook hands. And like, there is this one model of like all of this that's very purely biological, that we are just shuttles for the microbiota.

• 49:37Andrew D. Huberman?

  And everything that we're doing, like building electric cars and holding debates and protests and sending kids to school and all of that, we think is about us. But the microbiota are just like, they've hijacked this process. And like, they're not sitting there going, they think this is all about them and we're just trying to spread and make sure that we continue. And maybe long after they're gone, we're just going to keep going. And I can't poke any holes in this. It's like too good a theory. But I keep hoping somebody is going to tell me, at least from a purely biological perspective, that like, that's not true. But it kind of scares me. Every once in a while, I think like, maybe I'm just a bunch of microbiota.

• 50:16Speaker 00

  Yeah, you're just the vehicle.

• 50:18Andrew D. Huberman?

  We're just a shuttle, but we got this brain, which is very convenient for them, right? Because it makes me want to go out and do things. And I think about failures and successes and how I want to do better and what I want to do at different stages. And like, maybe it's just all about them getting as far and wide as they can.

• 50:33Speaker 00

  Well, unfortunately, Andrew, I'm not sure I'm going to be able to provide you the concrete proof that that's not true. It's a fascinating.

• 50:39Andrew D. Huberman?

  And kind of eerie, right?

• 50:40Speaker 00

  Yeah, very eerie. We definitely don't like to think of ourselves as anything other than the pinnacle of evolution and the reason for everything.

• 50:47Andrew D. Huberman?

  Right.

• 50:48Speaker 00

  But there's no question, to your point, the microbiome are the bacteria that live in our gut and on our skin. They're being driven by the same evolutionary pressures that we've been talking about for viruses and for us. They're trying to propagate themselves and fill the niche that they live in, fill the little chunk of the universe that they live in, and do it better than their competing neighbors. And if they can do that, then their genome is going to get passed on and again and again. And it's fascinating to think about the role that we play for them and they play for us. This is a phenomenon that's been known for a long time.

• 51:29Speaker 00

  But I think the implications of the microbiome is something that really has only been, I think, experimentally dealt with in a really serious way in the recent decade or so. And I think we're still learning about the implications, but there's no question that they're big.

• 51:44Andrew D. Huberman?

  Tell us about MPC 1 and 2. I'm asking about biochemical steps in a key process of energy production and allocation. And normally, when people hear acronyms, they don't understand. They kind of go, oh, goodness, like, what are we doing here? But like.

• 51:59Andrew D. Huberman?

  I think it's so important that people understand like this business of us, of this metabolism having energy, whether we're young or old, have a lot of it or less of it, healthy or dealing with cancer, like this is a key node. And what I want to know truly is, how do you actually discover something like this? Because, and this is where I think we can really illustrate the scientific process in a way that like, most people just don't understand. So you need cells, first of all, you need to be able to find the mitochondria, you need to be able to know what's ATP and what's pyruvate. And then you know they're going to two different pathways because someone else said that and you can observe it down a microscope. But then how do you find this thing? And then tell us what it's doing, perhaps, or tell us what it's doing. But I think it would be

• 52:43Andrew D. Huberman?

  very useful for people to get a picture of how this is done. Because we hear this stuff like, oh, this molecule, and people go, is there a peptide for that? It's like, hold off, let's think about how we come to understand these essential aspects of ourself, I think would be so useful.

• 52:58Speaker 00

  I appreciate you asking about that. It allows me to reminisce a little bit about the process of discovering that, which was, you know, a fun time in my career and was fueled by the brilliant people in the lab that did it. So MPC, this is a case where the acronym actually makes sense. It's the mitochondrial pyruvate carrier. So you don't have to be a scientist. We did not name it. That was, it was named before. I'll tell you that when I tell you about the story.

• 53:23Andrew D. Huberman?

  Because I don't like acronyms that aren't informative.

• 53:25Speaker 00

  MPC, aptly named, is the carrier that enables pyruvate to get into the mitochondria, mitochondrial pyruvate carrier. That's what it does. Sits in the mitochondria and basically provides a very specific hole in the membrane to enable pyruvate to get in, so that it can then be burned by the mitochondria to again, extract all the energy to make ATP. That's, that's basically what it does. The history of this is really interesting. It's been known for 60 or 70 years that mitochondria must have a carrier to enable pyruvate to get in. But it was not identified

• 54:04Speaker 00

  what that protein was, how it worked. And fast forward to 2008 or nine or so, and our laboratory had just recently become, again, fascinated with mitochondria. I would say the motivating piece of, of information that convinced us to start working on mitochondria was the realization that many of the proteins that make up mitochondria, that do the stuff that mitochondria do, we don't know what their functions are. And that suggested that this organelle, powerhouse of the cell, we kind of, I at least felt like we knew a lot about what mitochondria do. There's mysteries

• 54:47Speaker 00

  there that we don't have answers for. And so we started just taking some of these proteins that we know are in mitochondria, we don't know what they do, and trying to figure out what they do. And two of those turned out to be MPC1 and MPC2.

• 55:02Andrew D. Huberman?

  Way back when I observed and was taught, I didn't do a ton of this, that like, if you want to figure out what proteins are in a cell, you get a bunch of those cells, which you can do, and then you, you kind of grind them up, and then you run them through a bunch of columns, and like literally tubes. And those tubes have filters that either let big, less big, small, or very small things through, what we call fractionation, right? And then you kind of test the, the different stuff that comes through for its ability to do something in some sort of cell or that. It's like, how did you actually find MPC2? Was it done by like, sort of hardcore, what we call hardcore biochemical purification? That was kind of the old way of doing it? Or,

• 55:43Andrew D. Huberman?

  well, let me ask this. Do we know the total number of proteins in the, in a given human heart cell?

• 55:52Speaker 00

  I think we know, yeah.

• 55:53Andrew D. Huberman?

  We know everything that's in a heart cell.

• 55:55Speaker 00

  I think we know all the proteins in a heart cell. Again, you can get into the nuances of slightly modified versions, but we know the proteins because they are encoded by our genome, right? We know the human genome. That's been sequenced. We know what that is.

• 56:08Andrew D. Huberman?

  But we don't know that everything that's expressed in a given cell.

• 56:11Speaker 00

  That's right. That, that's true. And there, there are some very interesting features there.

• 56:14Andrew D. Huberman?

  Can I, sorry, I'm interrupting you on purpose. 20 years ago, could you say what you just said?

• 56:19Speaker 00

  With much less confidence than I, than I can now.

• 56:22Andrew D. Huberman?

  Say heart cell, but we don't actually know all this, all the bits in it. But now we do.

• 56:26Speaker 00

  Now, I think we, we know essentially everything. Again, there's going to be subtle nuances that we don't know, but I think we know almost everything.

• 56:34Andrew D. Huberman?

  That's good.

• 56:34Speaker 00

  Doesn't mean we know what all those things do. And that's maybe the frontier for the biochemistry frontier for the next generation of scientists to, to figure out. We don't know what they all do, but we know more or less what they all are. Knowing what they are, but not knowing what they do motivated us to go take these two proteins that were in the mitochondria. We could make a very strong hypothesis that they were important because they were in every cell that has mitochondria, down to a yeast, that's a single-celled organism, and plants and animals, everything

• 57:12Speaker 00

  that has a mitochondria has these two MPC1 and MPC2 proteins. And it would probably take too long to explain on this podcast, the processes that we went through to try to identify the function of this MPC1 and 2. But this was a, a brilliant collaboration, and I think one of the, the highlights of my career, different people in my lab and in the lab of my colleague Carl Thummel, that worked together. Carl was a fly geneticist, or is a fly geneticist, that used his unique skills and, and resources. And we were using yeast as a model system, as well as human

• 57:53Speaker 00

  cells, and triangulating all that data, we came up with data that suggested that this might be the mitochondrial pyruvate carrier, these two unknown proteins that happened to be sitting in the mitochondria. And that was now been validated many times over, that these are the proteins that do this transport of pyruvate into the mitochondria. It was a really fun time for me as a scientist to, to see that happen. And, you know, you kind of alluded to this when you asked the question, what was maybe even more exciting than the discovery of the mitochondrial pyruvate carrier, which Carl and I did, and we published a paper, and the lab of Jean-Claude Martin New in Geneva published a paper at the same time, showing the same discovery. What's been really

• 58:38Speaker 00

  fun since then is to see the implications of that, and starting again to understand what role this protein plays in the allocation of that pyruvate that we've been talking about. Because now the MPC is the first step towards one destination of that pyruvate. So it kind of pulls it into the mitochondria, so to speak. And once that pyruvate is in the mitochondria, it's going to be used for something in the mitochondria, instead of maybe being used for something else in the cytosol. And so that's been work that, that we've done a lot of since, is what are the implications of that? And I think it's been exciting to see in different

• 59:22Speaker 00

  cell types, what that means. And so cardiomyocytes, for example, again, these are cells that want to make ATP to, to allow cardiomyocytes to continue to contract. They need to extract every bit of energy they can, make as much ATP as they can. They use this MPC extensively.

• 59:42Andrew D. Huberman?

  How do they ensure that these cardiomyocytes make sure that they make just enough to maintain themselves? So they, they're not so busy burning up all the lumber that they end up going, oh my goodness, and the house fell apart? Do they consistently devote 90% of, of their ATP to energy utilization? And that they just know 10%? Like, how quantitative are these, these pathways? Because you can't, you can't have the walls fall down. It doesn't matter how much energy you produce.

• 1:00:09Speaker 00

  It's a brilliant question. And it's definitely not programmed. Like, like, there's a spigot with a diverter valve that 90% goes this way and 10% goes that way. What actually happens, and this doesn't just happen in cardiomyocytes, it happens in every cell, is that basically the cell is measuring the outputs. Again, to anthropomorphize, and I have to say, there are some scientists that hate us when we anthropomorphize cells.

• 1:00:35Andrew D. Huberman?

  I'm talking about humans having an intelligence or adaptive logic, so it's okay.

• 1:00:39Speaker 00

  I think you've provided cover for me to do it on, for cells then. Cells basically are measuring their resources all the time. I think you could make a compelling argument that every cell, almost all cells, know how much usable energy ATP they have all the time. And when it gets low,

• 1:01:03Speaker 00

  They will initiate a series of reactions to that, responses to that, to bring it back up. They'll turn off processes that use ATP. They'll start pulling glucose out of the circulation to make more ATP. There's this really profound response to ATP depletion. And I think that's true for many of the end products of our metabolic map. Again, these are the, the, the products of the metabolic map are the amino acids that make proteins and the nucleotides that are required to make DNA and RNA, our genome.

• 1:01:38Andrew D. Huberman?

  There's a greediness to all these cells. If the fat cells are greedy, you could really see a problem. Like if we're not ingesting enough glucose, let's, let's hold off on ketosis for a second and alternate metabolic pathways, we will touch on it. But if the fat cells are also very self-serving, then, you know, at some point, are they just forced to liberate this stuff? But like ultimately fat cells just want to get bigger and bigger. And that, but if this cardiomyocyte, it doesn't have enough glucose. Eventually it's like, it could shut down any number of things. Like you can remodel a house down to, you know, just the fireplace and a little bit of structure around it, but eventually you need the resource. So then what happens? The adipocyte liberates the energy and, and cells, everybody gets a little bit and you just hang on. So it's a famine.

• 1:02:23Speaker 00

  Yeah, exactly. I mean, just as insulin tells the body, I just ate, we're good. Take that energy that's available in the form of glucose, squirrel it away, use it. There are hormones that do the opposite. Glucagon is one of them and glucagon again, has become a little bit more popular recently because it's now being combined in some of the GLP-1, uh, more newer GLP-1 drugs. Glucagon is called a fasting hormone. So glucagon in many ways does the opposite of insulin. It will go to the fat cell, bind to the fat cell, tell the fat cell to take the fat that it has squirreled away and release it.

• 1:03:06Speaker 00

  And now that can go to other cells in the body, the heart. Heart is very good at consuming fatty acids that come from adipose tissue. And so, so

• 1:03:15Andrew D. Huberman?

  That's good. I'm actually relieved to hear that.

• 1:03:18Speaker 00

  Yeah.

• 1:03:18Andrew D. Huberman?

  Right? Because if, if God forbid, there's a shortage of food that lasts long enough, like that's definitely an organ I don't want shutting down.

• 1:03:26Speaker 00

  Exactly. And, and most of us have fat in our fat cells and, and you could make an argument that the key destination of that fat is the heart to keep it alive. And, you know, in a normal human, I think it's estimated 70 to 80% of the energy extraction that happens in cardiomyocytes and heart muscle cells is happening from fat.

• 1:03:49Andrew D. Huberman?

  You said under fasted conditions.

• 1:03:51Speaker 00

  Especially under fasted conditions, but even in fed conditions, fat is, is, uh, is available for the heart to use and

• 1:03:58Andrew D. Huberman?

  Dietary fat or fat from adipocytes?

• 1:04:00Speaker 00

  Both. Whatever fat is in the circulation, the cardiomyocyte is pretty good at taking it up and burning it, making ATP from it.

• 1:04:07Andrew D. Huberman?

  The brain likes glucose, but it can use, maybe now we, I'm not super versed in, in the ketogenic pathways, but I know that our brain can thrive on ketones. So carbohydrates are not quote unquote essential.

• 1:04:19Speaker 00

  Yeah.

• 1:04:20Andrew D. Huberman?

  You know, all the ketogenic folks love to say that. There's no such thing as an essential carbohydrate. That doesn't change the fact that like the preferred fuel source for most every cell is glucose. But anyway, that's a separate issue. You don't want the brain to shut down either.

• 1:04:31Speaker 00

  Yeah.

• 1:04:32Andrew D. Huberman?

  So if the form of energy changes, is it still, once you get to mitochondria, pyruvate, MCP and downstream, is it all the same? Is essentially like energy is energy at that point? Or is, or is there, are there multiple pathways depending on the fuel source?

• 1:04:50Speaker 00

  Yeah. The ability of neurons to consume fatty acids is limited. I think it's traditionally been thought that it's very close to zero. I think that's being questioned now, but it's limited. As you allude to, neurons are particularly fond of consuming glucose and use that glucose to make their ATP. And, you know, that obviously puts a very stringent demand on the body to always have glucose available. Glucose is one of these things that's fascinating, the, the systems that we have in our body to maintain glucose, you know? Diabetes is defined as high blood sugar. That is the definition, the clinical definition of diabetes, when basically our body does

• 1:05:35Speaker 00

  not adequately limit the circulating glucose. And that is destructive, damaging, but it's damaging on the, in the course of years, right? A person can live with diabetes for years before succumbing to it. If glucose is too low, you die within minutes, not seconds. And that, I think for a few different reasons, but probably the most important one is the brain requires some amount of glucose to keep it functioning. So, you know, again, I, I alluded to this before, this very elaborate dance that is happening by these individual cells, taking up different nutrients out of the circulation, using them for their own unique purposes.

• 1:06:20Speaker 00

  And, and neurons again are, are very adept at taking in glucose and burning it and making ATP from it. I think again, the heart, I feel like is really fascinating because it'll, it'll eat anything. It's an omnivore. Fats, glucose, lactate, ketones, amino acids. It will make ATP out of just about anything that ATP can be made out of. And again, that's important for us to enable us to live no matter whether we just ate or not. Heart is very good at that. So I think this elaborate dance that we have going on in our body all the time between different cells, cells doing it different way, taking in different fuels and, uh, using them for their unique purposes.

• 1:07:03Andrew D. Huberman?

  What is the consequence of eliminating the MCP shuttle? Like do you get, like if you take a mouse, you're at the University of Utah, let's give a shout out to Mario Capucci, whose life story is amazing, who won a Nobel Prize for essentially developing what are called knockout mice, among other things. You can eliminate genes to test the role of a particular protein downstream of that gene. If you make a mouse that lacks these proteins, do you get a dead mouse?

• 1:07:28Speaker 00

  They do not survive to birth. Yeah.

• 1:07:31Andrew D. Huberman?

  You can get sperm egg and that somehow the, it can become a mouse.

• 1:07:36Speaker 00

  Yeah, it'll start to develop. And then I think if I remember right, it's about 12 or 13 days of development, which is, you know, two thirds of the way from fertilization to birth of the mouse, it will die and, and you won't get a live mouse. But what has been done, and, and obviously you're probably getting there, is because of the technologies that Mario developed and then others following after him, we can now make mice that lack the MPC only in the liver or only in the heart or only in the muscle or only in the brain. And many of these things have been done.

• 1:08:07Andrew D. Huberman?

  Sorry, I should have been given credit. He developed a technology that would allow for organ and cell type specific deletions or additions of genes, forgive me, but you reminded me like in homage to him.

• 1:08:17Speaker 00

  So, yeah. And many people have been contributing that technology and different ways to use it for decades now. And as you might imagine, given the unique demands of different cells, the effects are different. The heart is again, very focused, its metabolic program is focused on generating ATP. So what if we eliminate the MPC in the heart? So we have now made ATP generation from glucose less efficient. We've, we've now cut off the ability to use mitochondria, at least in the conventional way. So I actually think the results of that experiment are fascinating. And this is work that has been done by a few different labs. Akhmed Clinton, who's a postdoc now running his own lab at Rutgers, was the one who started

• 1:09:02Speaker 00

  this and other people have contributed. What essentially happens to that heart is that it lives and the animal lives for weeks after that. But eventually the animals die. And when you look at what they die of, they have a massive heart, they die of heart failure. And what has become clear as we've gone and done more sophisticated analyses of this heart and why they die? It's pretty clear that they don't die from an inability to make ATP.

• 1:09:37Speaker 00

  Because they can burn other things to make ATP. We talked about this. They can burn fats. They burn fats just fine. What they appear to die from, and I would say, I'm speculating a bit here. We don't have all the answers to all the questions, is they have made a resource allocation decision that turns out to be pathological for them. And instead of using the glucose that they take in to burn it and make ATP, they start making biomass. That, again, we talked about that, that bifurcation. We've eliminated their ability to make ATP from it, at least as effectively. And instead, they make biomass. They grow. And when cardiomyocytes grow,

• 1:10:16Speaker 00

  that creates structural problems for the heart. Almost every human that succumbs to heart failure will end up with a big dilated heart that's less effective at pumping. And that's what we see in the mouse.

• 1:10:30Andrew D. Huberman?

  Really?

• 1:10:30Speaker 00

  And that maybe tells us something about the fundamental importance of this resource allocation decision. And this is obviously just in the context of cardiomyocytes. But again, that resource allocation decision is happening in every cell in our body all the time. And that's one reason why I'm fascinated with this field, is we're just starting to understand how those resource allocation decisions are made, what are the implications of making them correctly and incorrectly, and maybe even more excitingly, can we go and fix that? When a cardiomyocyte, or when a heart, more aptly, is making a resource allocation decision

• 1:11:11Speaker 00

  that is pathological, can we fix it? Can we find a therapeutic that will go and correct that? And rewire it in the appropriate and healthy way? And can that then restore the proper function of the heart? Again, I think we're at the frontier of this field, but it's a really exciting place that our field exists now, where we're starting to understand the problems. And we're starting, I would say, early in developing the right agents to act and to manipulate this metabolic map that might be able to fix things.

• 1:11:46Andrew D. Huberman?

  I'd like to take a quick break and acknowledge our sponsor, Function. Function provides over 160 advanced lab tests to give you a clear snapshot of your bodily health. This snapshot gives you insights into your heart health, your hormone health, autoimmune function, nutrient levels, and much more. They've also recently added access to advanced MRI and CT scans. Function not only provides testing of over 160 biomarkers key to your physical and mental health, it also analyzes these results and provides recommendations for improving your health from top doctors. For example, in a recent test with Function, I learned that some of my blood lipids were slightly out of range. As a result, I decided to start supplementing with nattokinase,

• 1:12:27Andrew D. Huberman?

  which can naturally help reduce LDL cholesterol. And it did. In a follow-up test, I could confirm that this strategy worked. My blood lipids are now back exactly where I want them. Comprehensive lab testing of the sort that Function offers is just so important for health. I mean, how else are you going to know what's going on under the hood? And while I've been doing blood work for years, it used to be time-consuming, complicated, and expensive. In fact, I used to spend thousands of dollars per year trying to get this kind of data. And the data, frankly, were not all that good. But now with Function, it's extremely easy and affordable. A Function membership is only a dollar a day, $365 a year. And if you think about the information it provides, and the health challenges it helps you avoid, and the proactive things that it can do

• 1:13:09Andrew D. Huberman?

  for you to enhance your health, I truly look at it as a savings. To learn more, visit functionhealth.com/huberman and use the code HUBERMAN for a $50 credit towards your membership. Again, that's functionhealth.com/huberman. So is it fair to say that the allocation of energy, which is made pathologic in this mutant mouse, but also in people who have these cardiac conditions and die of heart attack, essentially, it's almost like the identity of the cells is screwed up. They're still a cardiomyocyte, but they're devoting too much energy to making more of themselves and not enough to doing what they're supposed to do. I have like two analogies that I want to throw out there, and maybe they're

• 1:13:50Andrew D. Huberman?

  too much of a reach, but I love dogs. I have now a medium-sized dog. I used to have a large dog. The larger breeds of dogs live much shorter lives than the smaller ones. And we actually know that's because of dosing of IGF-1, which is a growth pathway thing. So there is this like story about larger animals within a given species tend to live much shorter lives than the smaller variety of that same species. There's some exceptions to this, but there does seem to be a sort of rule that like you can either be big and live a short life, or you can be small and live a longer life within certain species. But there's also this thing about heartbeats, right? Like this theory that you only get so many heartbeats in your life. The reason I like these

• 1:14:32Andrew D. Huberman?

  higher level, perhaps, appropriate comparisons, a lot of caveats there, is that like ultimately, when I think about life and evolution and propagation of species and health versus pathology, it's all about energy, right? It's like, how are you devoting energy? It can get into the kind of mystical spiritual piece. That's not our purpose. It's not my purpose in bringing this up now. But it seems like at the cellular level and at the subcellular level, which is what you're describing, the allocation of energy, in this case, is the difference between life and death. But this decision, you're not telling us like, oh, you know, these pathways I discovered along with others are really like, there's a fan out of like 50 different options.

• 1:15:16Andrew D. Huberman?

  You're saying make more biomass, more of self, or use energy to be self. And there seems to be like a critical balance there. And I have another story I could tell about how like, if you look at the data on longevity in different athletes, like the gymnasts, the sprinters seem to live three to six years longer on average than others. And the endurance runners are somewhere in the middle. You look at very large athletes, like the powerlifters and the, moving aside all things of like use of drugs and sports, I think you go like, the sports where there's just a lot more of a somebody, that's not good for longevity. And it really isn't. So there does seem to be this balance between size and the use of fuel to build more of oneself

• 1:15:59Andrew D. Huberman?

  and the use of fuel to just be oneself. And that self could be a cell. That self could be an organ. That self could be a whole organism. And I find that like not incidental, but maybe I'm taking too many liberties here.

• 1:16:13Speaker 00

  Yeah. I mean, that's a, that's a complex analogy. And, but I think one thing that is very clear about, about what you're talking about is this sense of, of identity in a cell. That's a fundamentally important phenomenon that, again, we've known about for a long time. And there's been an understanding in some cell types in some ways about how that identity is established and maintained. But I think your question is a really interesting one. To what extent is disease associated with loss of that cell identity? And, and cell identity is a bit of a squishy parameter. You know, how do you measure what a cell thinks it is? You know, there's no way to ask.

• 1:16:54Andrew D. Huberman?

  Function, right? So, yeah, like when we had Max Crummell on the podcast, he was like, you know, every one of your cells, by the time you reach our age, roughly, you know, in our 30s, no, I'm kidding, in our 50s, early 50s, is we're a mosaic of like our original genetic makeup, plus all these mutations that have accumulated. Nobody likes that picture. That's true. We're a patchwork of like our former self and our newer self. That's one form of cell identity. What I like here is that you're talking about within an organ, within a cell type, you sort of have a choice of A, make more of oneself, or B, just be you. So there's something like, kind of like, to me, conceptually sticky about this notion of size versus use.

• 1:17:35Speaker 00

  Yeah, I think, as you say, I think that in a way, we're talking again about resource allocation, allocating to energy versus making more stuff that could mean another cell or a bigger cell. There's many examples of where making more stuff, instead of making more energy, is pathological. We talked about cancer. We talked about the heart getting pathologically bigger. Immune cells becoming hyperactivated can lead to inflammatory diseases. You know, there's many examples of that. So I think this is all playing out at the level of individual cells. And what you're talking about is obviously a bigger conceptual framework in which to think about it.

• 1:18:16Speaker 00

  But I think there is that connection. And I don't know, this is a bit non-scientific, but I do think it's fascinating to understand the historical, philosophical ways that our ancestors thought about the world. And we find relics of that in our science, right? That we can see reflected in the discoveries that are made today.

• 1:18:41Andrew D. Huberman?

  I don't want to take us off the biology, but if we can go down this pathway a little bit more. You know, I sometimes think about energy in terms of human interactions. And I think most of us can think of the extremes of benevolent versus malevolent energy exchange. Like, like, let's say somebody, like money is just a tool, right? Like, people say money is energy. That sounds very, you know, like internet-y, but really, it can be exchanged for something, right? We've decided that. And if somebody steals from us, or they, they promise something, and it turns out they overcharge us or something like that, like, we fundamentally understand the math there. You said it was going to cost this. I'm not saying it cost me. You said it was going to be this, and instead I got that. And this isn't what I paid for, right? But if you look at human interaction and behavior,

• 1:19:23Andrew D. Huberman?

  the stuff that we consider malevolent is usually when something, when someone perceives it, the energy has been stolen from them, usually in the form of time, but often in the form of physical energy, because time is physical energy, right? And then benevolent acts are generally ones in which there's either an even or a kind of a, like a net positive exchange of energy. And this is like a lot of what structures human interactions. Like, I don't want to take us too far. This is not a psychology podcast, but I think about this all the time. And like, why I like zooming down at the level of the cell is we can find, there isn't going to be a perfect relationship between the cell and human interactions at large. But this notion of no cell, if it wants

• 1:20:06Andrew D. Huberman?

  what's best for itself, and therefore the organ it resides in, and therefore the organism, can afford to really cheat itself.

• 1:20:16Speaker 00

  That's right.

• 1:20:17Andrew D. Huberman?

  Like, bring it down to like the individual cell. You can't, like, the cell can't afford to cheat itself. And if too many cells do that, you end up with a big heart that doesn't pump.

• 1:20:26Speaker 00

  Exactly.

• 1:20:27Andrew D. Huberman?

  So it cheated itself. For me, that's very useful. I don't know if it is for anyone else. So when I think about like really critical biology.

• 1:20:36Andrew D. Huberman?

  All these proteins, like which ones are going to study? Like, it's clear to me now why this set of proteins is very important.

• 1:20:41Speaker 00

  Yeah.

• 1:20:42Andrew D. Huberman?

  Very, very important. What I didn't get was how you actually found it. So was it that you knew there was a gene there that coded for this thing of a certain size? So you started making some, what we call recombinant version of that and like throwing it on cells, seeing what happened? Is that kind of the steps that went through?

• 1:20:56Speaker 00

  We knew the protein was there. What we didn't know is what it did. And I would say the key discoveries of that came from genetics. Basically Carl's lab made flies that lacked the MPC.

• 1:21:10Andrew D. Huberman?

  Dead fly?

• 1:21:12Speaker 00

  They were actually alive. There's an interesting story there that's probably too in the weeds, but they live, but they had specific manifestations that we could analyze using chemistry. And I'll tell you about the results of that. We were studying in other, in other cell types and yeast cells and in human cells and studying the results of losing these genes. You know, again, this is what's enabled by doing genetics. You know, Mario Kopecky figured out how to do this in mice and his colleagues. That gave us the ability to do knockout mice. Other people have enabled it in other species. And by doing that and studying the results, we could then deduce,

• 1:21:55Speaker 00

  oh, what's happening in these yeast cells, these fruit flies and these human cells grown on a dish? Is they aren't able to take their pyruvate into the mitochondria. You know, by analyzing them using sophisticated chemical tools, we could see that they were basically their metabolic pathway from glucose to pyruvate to pyruvate in the mitochondria to ATP. That was being blocked and it was being blocked specifically at that level of the pyruvate. So that then gave us the initial hypothesis. Maybe that's what these proteins are doing. And we could then go and validate that hypothesis in multiple experiments. And that, like I said, been validated by many other people over the ensuing decade or so.

• 1:22:40Speaker 00

  So those were the experiments that enabled us to, to figure it out. It was really genetics that enabled us to do it.

• 1:22:47Andrew D. Huberman?

  Very satisfying when a discovery comes about in yeast flies and mammalian, including human cells. What year span was all of that happening? If you had to really tighten it to-

• 1:22:58Speaker 00

  Yeah, we published the paper in 2012. It probably was going on from 2008 or nine to 2012, something, something like that.

• 1:23:06Andrew D. Huberman?

  This is actually an important moment, I think, for people to understand. Like when they hear about yeast or flies, they're probably like, like, why, why are we doing this stuff? And I'm not here to like plug federal funding for research. I think that just happens naturally as a consequence of the podcast, or at least I hope so. But my graduate advisor told me that yeast, like they have a very quick turnover. So that's why they're good to use. And, and she said that, um, she was a wine drinker. She said, and they are much smarter than us because they know how to make their own alcohol. So now we know why biologists use yeast. Fruit flies, it's because of the short generation time. You can get a lot of experiments done.

• 1:23:38Speaker 00

  And they, they have many of the, the same structures that a human does. You know, not exactly, obviously, but they have many structures that human does. And there's some things that are particularly good at. You can look at the whole thing in the microscope and see different cells and different features. And I would say, again, not to plug our specific experiments, but we could not have made that discovery with any one type of organism. If we just had the yeast data, we wouldn't have figured it out. If we just had the fly data, we wouldn't have figured it out. Same with the, the human cell data, but putting it all together, we could triangulate what we were seeing in one to what we were seeing in the other. And it became obvious that this is the hypothesis we should pursue. And I, I think that's been obviously an effective strategy that's been employed by scientists for a long time

• 1:24:22Speaker 00

  is to take multiple different approaches, multiple different model systems to answer a complicated question.

• 1:24:29Andrew D. Huberman?

  Let's talk about lactate. Every time lactate's come up on this podcast before, it's been in the context of exercise physiology. We had the, the great Andy Galpin, whose name I don't expect you to recognize, but he's, he's really one of the like preeminent public educators. He's a professor of physiology and exercise physiology. And he told us and he told the world, like everyone talks about lactic acid. We don't actually make lactic acid. We make this thing called lactate. But within the cell, lactate plays a very crucial role in this metabolic pathway. I know you've spent some time with lactate. So when you think about lactate, what do you think about?

• 1:25:03Speaker 00

  I mean, so pyruvate, we talked about pyruvate extensively. To a first approximation, again, it's a little more complicated than this, but I think this is a good way to think about it. When pyruvate is made, simplistically has two fates. It can go into the mitochondria we talked about. What we didn't talk about is the other major fate is to be converted to lactate and exported. And that decision, burn it, make lactate. I think you could make a very strong argument is one of the most important metabolic decisions that cells are making all the time.

• 1:25:32Andrew D. Huberman?

  Why would it not burn it or make more of itself? Cause it's just got it in excess?

• 1:25:36Speaker 00

  Yeah, there's something about that production of lactate that enables ongoing production of biomass. So again, a little more complicated than this. If you burn the pyruvate, that turns into carbon dioxide, we breathe it out. That the stuff is gone. We breathe it out. There's no stuff, there's just the energy. If you don't burn it, that stuff doesn't get eliminated as carbon dioxide and can turn into a protein, can contribute to protein production or carbohydrate production or, you know, fatty acids that can be used to make, make new cells. And so that really is the, that resource allocation decision that we talked about many times. Building or burning?

• 1:26:21Speaker 00

  And lactate is one of the mediators in a way of that building decision. And so lactate, I think historically has been thought of as a waste product. When our cells can't burn, typically because of lack of oxygen. We haven't talked so much about the role of oxygen and all this. When I talk about burning, what I really mean is taking that pyruvate or fatty acids or other things and oxidizing them using oxygen. And by so doing, extracting the energy and doing this unbelievably amazing chemistry that the mitochondria do to basically very effectively capture all that energy and make it usable in the form of ATP.

• 1:27:04Speaker 00

  When oxygen isn't available, that pyruvate cannot be burned. And then it essentially has to be converted to lactate. That's why when we exercise and our muscle becomes hypoxic or doesn't have adequate oxygen, we make lactate and that lactate is what causes the burn that we feel. And we've thought about it traditionally as a waste product. There's been beautiful experiments done in the last five or 10 years. Joshua Benowitz, a friend of mine and professor at Princeton, has done some of these that have demonstrated that lactate is a very important fuel on its own. The heart, for example, is quite good at consuming lactate and burning it.

• 1:27:40Andrew D. Huberman?

  The heart can, it seems like it's kind of like a, it's got, it's consuming a sort of like dog's breakfast of fuel. It likes lipids, it'll take glucose, it likes lactate.

• 1:27:50Speaker 00

  Anything. That's good for us because that, that keeps it beating no matter what the metabolic status of, you know, as long as we're alive, we have something that it can burn. And lactate is just an important mediator of carrying the, that energy around.

• 1:28:03Andrew D. Huberman?

  It can be a fuel, it can be a shuttle. In the context of exercise and brain, and I know this, we're not talking about actionables here, but like I've mentioned before on this podcast, like if we do like an intense, typically it's aerobic exercises where you get like enough lactate generated. That does seem to be a signal to the brain for this brain derived nootropic factor, which now kind of makes sense in this context, because the whole purpose of BDNF is to build more stuff, more connections typically, rather than break connections. So it's amazing that we think of these things as like a waste product, just like we used to talk about like junk DNA. Nobody does that anymore. But to be very careful with language in biology, I'm realizing.

• 1:28:42Speaker 00

  Yeah.

• 1:28:43Andrew D. Huberman?

  Like the moment we, we label something conceptually, you like shut down a field and like a line of discovery that almost always ends up being like super important.

• 1:28:52Speaker 00

  Yeah. We joke all the time in the mitochondria field about the powerhouse of the cell, right? Which it really is. I mean, the mitochondria are very good at being a powerhouse and making ATP, but they do so much more. And again, just to illustrate the point that when we categorize something into one thing, this is what it does, we're almost always proven wrong. And it turns out to be a bit more complicated.

• 1:29:12Andrew D. Huberman?

  There's something I can't wrap my head around because if I have an excess of energy and therefore I'm making lactate, am I going to now prioritize lactate? Is that going to now get burned off the top of the energy priority scale?

• 1:29:24Speaker 00

  That's a good question. And, and you know, I, I don't think we have strict answers to this, but there's definitely prioritization of energy. One of the most important things to burn is fatty acids. And, and the reason for that is that when fatty acids are in excess, they can be toxic. And they can be toxic in an acute way, quickly. Glucose, again, is toxic in excess, but chronically. Maybe it's a little bit less dangerous if we have high glucose for, for some time. High free fatty acids is dangerous now.

• 1:29:55Andrew D. Huberman?

  And not just because it clogs arteries.

• 1:29:56Speaker 00

  That, of course, yeah, exactly.

• 1:29:58Andrew D. Huberman?

  Yeah.

• 1:29:59Speaker 00

  It, yeah, in ways that we probably don't need to get into, but it can be disruptive just to cell structures and so forth. And so, you know, most cells, when they have fatty acids, will burn the fatty acids first, probably as a response to, hey, this could kill us. Let's, let's take care of this first.

• 1:30:19Andrew D. Huberman?

  It's also true, the fatty acids we ingest.

• 1:30:21Speaker 00

  This is also true, the fatty acids we ingest, if they get into cells, of course, you know? You could imagine, again, it's a little more complicated than this, but the fatty acids we ingest and the fatty acids we make end up in the same pathways, right? They, they both get into other cells throughout the body. And when they do, they need to be handled appropriately. Lactate is maybe a little bit more on that, on that side. It, it has some important effects to the chemistry of cells that are important to deal with. And so lactate, if it, if it gets too high in the body, it can be toxic, you know? Lactic acidosis, which is essentially the, the phenomenon where we have too much lactic acid,

• 1:31:03Speaker 00

  lactate in our, in our circulation, that's bad and can be lethal. And so dealing with that lactate is important. And so, yeah, I think there is a prioritization that probably comes as a result of evolutionary pressure. You know, we had ancestors that maybe didn't deal with fatty acids so well. And maybe didn't survive, but we had one individual that figured out how to deal with them more effectively. And that individual survived better and that trait was selected for, and we're now pretty good at it.

• 1:31:32Andrew D. Huberman?

  We had a colleague of yours on the podcast who studies hypoxia and spleen function. And we're talking about how everyone hears the word mutation and they think like, oh, mutations are just always damaging. But you know, these mutations that afford more life, that are adaptive essentially, people can't hear that enough.

• 1:31:49Speaker 00

  Yeah.

• 1:31:50Andrew D. Huberman?

  Mutations are the reason we're here.

• 1:31:51Speaker 00

  That's right.

• 1:31:52Andrew D. Huberman?

  Yeah, so the X-Men had it right. That's a good series to watch. On the other side of the coin, the maladaptive situation, could you tell us about the Warburg Effect and its role in cancer? And I do want to frame this properly because nowadays, we're living in a weird time around this topic of cancer. There are these corners of the internet that like, don't actually believe in cancer or germ theory. They just like, don't believe it. And some of that is actually kind of catching on. I believe cancer exists and I believe that cancers can come about through a variety of mechanisms. So only if you believe that to be true, that it can come about through a variety of mechanisms, would I ask you to like, agree. If you disagree, please disagree. But it's true, right? That there are a lot of paths to cancer.

• 1:32:37Speaker 00

  Yeah, there's no question that there are some fundamental features of cancer. All cancers, to my knowledge, have mutations in the genome. And those mutations are many, but tend to cause, again, work together to cause that cell to divide, to replicate itself more rapidly, to evade the immune system, which is patrolling, looking for misbehaving cells and to eliminate them. And somehow cancer cells can avoid that. Critically important. And you know, one of the most exciting developments in cancer therapy over the last 10 or 15 years has been these checkpoint inhibitors, PD1, PDL1 inhibitors, that basically reverse

• 1:33:21Speaker 00

  that, you know, cancer cells are very good at cloaking themselves, let's say, from the immune system. And those therapies eliminate that cloak and, and allow them to be seen by the immune system and eliminate it. And there's just been amazing responses to those new therapies. Again, they don't treat every cancer to the same degree, but there's been wonderful examples where they've been effective. So yeah, cancers can arise through many different pathways. They all are associated with mutations. One of the common features of cancer is changes in metabolism. And this is, when you talk about the Warburg Effect, this is really fundamentally what you're talking about. So the Warburg Effect is a phenomenon that was named after Otto Warburg, a scientist,

• 1:34:05Speaker 00

  a German scientist, back in the 1920s, that observed that cancer cells consumed less oxygen than would be expected from the cells around them. And that has been named the Warburg Effect. What Otto Warburg thought was that that's because the mitochondria are broken. And then concluded that broken mitochondria are probably the cause of cancer. That was the thinking that permeated from the time of Otto Warburg in the 1920s for many years.

• 1:34:41Andrew D. Huberman?

  Broken meaning they're not making ATP or they're, they're doing something wacky?

• 1:34:45Speaker 00

  Yeah, they're, well, they're not consuming oxygen. That was the observation. The oxygen consumption was low. And that is, again, mitochondria as the powerhouse of the cell are consuming oxygen. That's how they're doing their powerhouse function, making ATP. So that was the observation. The interpretation of that observation was that mitochondria are probably broken. We now know, we've talked about this, that mitochondria do more than just make ATP. And it turns out that mitochondria in cancer cells are not broken. In fact, they're very, very good, not necessarily at making ATP, but at making stuff. And again, the stuff is what's so important for a cancer cell, because it needs to divide itself. It needs to duplicate itself to eventually make a tumor.

• 1:35:30Speaker 00

  So the Warburg Effect is a phenomenon, again, in simple terms, that is absolutely the case, that many cancer cells, most tumors, consume less oxygen than you would imagine, because they're, instead of burning their fuel, again, we talked about this bifurcation, cancer cells tend to not be burning, and by burning, that's consuming oxygen, but they're using their resource allocation to build stuff, to build a new cell. And so I think this dovetails very nicely with what we've been talking about before. The oxygen consumption, the Warburg Effect, is basically just a surrogate for that resource allocation question.

• 1:36:12Speaker 00

  And cancer cells are, are very adept at using their resources to duplicate themselves.

• 1:36:18Andrew D. Huberman?

  Of the modern treatments for cancer, radiation, chemotherapy and immunotherapies, and what's happening now, I had someone on talking about, you know, CAR-T cells and things of that sort, but is there anything that you kind of sense on the horizon, it might be five, 10 years out or two years out, that like, if we could just solve that, that we would be in a position to treat and cure many more cancers? Like, what's the, what's the kind of linchpin thing here? Is it being able to reallocate the use of pyruvate? Like, if we could do that, if that was a druggable thing, or you could do a gene therapy, but, or you could use non-invasive tools like ultrasound or light?

• 1:37:02Andrew D. Huberman?

  Like, these are all just forces, right? Chemical or, I would like to simplify things like for people if possible. Like, there are two ways to change things in the body, healthy or unhealthy. You have mechanical choices and chemical choices, right? You can feel more full by having your gut distended, you can feel more full because your hypothalamus says you're full. And there's a bunch of other stuff involved, but like, that's all we've got, is mechanical and chemical forces.

• 1:37:21Speaker 00

  Yeah.

• 1:37:21Andrew D. Huberman?

  So let's assume you had the tool. Is there someplace where like, you feel like if we could just turn that bolt, we would be in a much better position to treat a lot of cancers or cure them?

• 1:37:33Speaker 00

  Let's maybe take a step back from that and then get to that question in a second and talk about cancer, you know, what it is and why it's so difficult. If a bacteria invades us, it's very easy for our immune system to say, hey, that's not us, let's go kill that thing. If a cancer cell starts hyperproliferating, it's us, right? It's our cells. It doesn't have antigens, which are the technical term for the molecules, the features that are recognized by the immune system. It doesn't necessarily have antigens that are recognized as not us, non-self. So that's one of the big challenges of cancer.

• 1:38:16Speaker 00

  The challenge for us is to figure out a way to kill those cells, which again, are our cells, they are us, is to kill those cells without killing the rest of our cells. Because if we kill the rest of our cells, we kill us, right? That's the challenge of cancer therapy, in my view. Again, I'm oversimplifying, but that's, that's a big challenge. And many of the features of cancer cells are not completely new things that that cancer just invented. It's using the functions that our normal cells have. For example, one of the things that's common, not universal, but common in cancer cells, is to become more like a stem cell, has many features of stem cells.

• 1:38:59Speaker 00

  So, okay, we can find a way to target a specific stem cell pathway and kill all the cells that have that. Well, then we're killing many of our stem cells too. And now the lining of our gut doesn't regenerate, which we talked about, that's driven by stem cells.

• 1:39:15Andrew D. Huberman?

  Hair falls in.

• 1:39:16Speaker 00

  Exactly. This is obviously one reason why many of the, the side effects of chemotherapy is to target those proliferating cells, which share many features with cancer cells. So that's the problem of cancer therapy. And there's a second problem that we're talking about too. We've talked about evolution a lot here, which I think is, it's a great rubric by which to think about biology. Cancer cells, a tumor, is under evolutionary pressure, right? So we now, let's take an example where we have a tumor. And we get a drug, we have a great drug that kills 99.9% of the cells in that tumor.

• 1:39:58Speaker 00

  But 0.1% of the cells, either through a mutation or some sort of an adaptation, are not killed by it.

• 1:40:05Speaker 00

  But that 0.1% can now repopulate, make a new tumor. And this is what happens in cancer therapy. We all know tragic examples where we loved ones had a tumor, got a treatment, and they went into remission. You know, the tumor maybe shrinks, it goes away, maybe even becomes invisible by the imaging tools that we have to image cancers. But then it comes back. And that's because these cells are under evolutionary pressure. If one cell theoretically, one cell acquires a mutation that makes it resistant to that drug, doesn't get killed by that drug, that one cell can now repopulate, make a new tumor and be just as damaging. And now it's resistant to the drug.

• 1:40:50Speaker 00

  Now the drug doesn't work anymore. And this is the second big problem with cancer therapy. You know, this is not my field of expertise per se, but I feel like, given that situation, this is not dissimilar to what happens with viruses. HIV now can be managed and frequently is managed by a triple combination therapy. And the reason for that is you now give three drugs that are going to kill that virus or prevent the propagation of that virus. It's now very difficult to acquire resistance to all three simultaneously. I think the analogy applies to cancer too. I think the future of cancer therapy,

• 1:41:34Speaker 00

  again, in my worldview, is going to be, we have many safe and effective drugs that hit different features of the cancer cell's biochemistry. And by virtue of understanding the specifics of the tumor that I might have, the astute oncologist can say, given that unique biochemistry of that tumor, this drug, this drug, and this drug are going to work together to kill that tumor. And it's going to be very hard for that tumor to become resistant to all of those drugs simultaneously. And as a result of that, that might result in something approximating a cure. I think that's the world that we need to get to.

• 1:42:17Speaker 00

  So there's been amazing therapies that have come out. You know, one of the most exciting recently are drugs that target specific oncogenic mutations, specific mutations that cause cancer, KRAS mutations, one that are really exciting, that target specific proteins that are contributing to the cancer in a completely specific way. Don't do anything else in the body to normal cells. Only hit those mutations that are oncogenic. But again, eventually, there can be resistances acquired to that. So if we can now make multiple examples of that kind of specific, safe kind of drug and use them in combinations, our ability to treat cancer is going to be dramatically improved.

• 1:43:00Andrew D. Huberman?

  That's very encouraging. We had a guy on the podcast named David Faganbaum. He's a medical doctor. Are you familiar with his work? He's at University of Pennsylvania. He had Castleman's disease and he was able to cure his own Castleman's disease because he was basically on his deathbed. And he basically just started taking different combinations of already approved drugs in a kind of desperate attempt to save his life. And he found things that would extend his life. And he's been alive 11 years now. And he runs a lab, serious scientist, as we say, but he also has this not-for-profit called Every Cure, which has been successfully using AI and cell assays and things to take tumor biopsies and try and figure out like, okay, in this tragedy of a kid who's dying of a particular cancer, like, let's just throw a bunch of not random drugs,

• 1:43:45Andrew D. Huberman?

  but already approved drugs at this tumor in a dish. And if some of them work, like, if the parents agree and there's no other hope, do it. And like, in some cases, they're curing. And in many cases, they're extending life. It matches up well with what you're describing. It requires this AI piece to run iterations because there's a huge catalog of drugs that even oncologists might not be aware of. One particular highlight of his work is that we know now that in breast cancers where they use lidocaine during the surgery, the incidences of recurrence are significantly lower. And it turns out that lidocaine has some effect on the local environment. I'm not, this isn't my, but you know, David talks about this. And I'm encouraged by things like that and what you're describing, that we're not necessarily going to have like the miracle drug,

• 1:44:29Andrew D. Huberman?

  but then the miracle cocktail for that individual, that cancer.

• 1:44:34Speaker 00

  Yeah, that's the key thing is that, you know, David's situation is very specific to David and every tumor is a little bit different.

• 1:44:43Andrew D. Huberman?

  Yeah.

• 1:44:44Speaker 00

  And one of, I think, the unhelpful results of historically how we talk about tumors is we talk about breast cancer or liver cancer or, you know, colon cancer. There are some breast cancers that are more similar to some liver cancers than they are to other breast cancers. Right? This is our historical classification of cancer has just been by where it is, just defined by the surgeons that would take it out. But the specific mutations that cause that cancer and keep that cancer, again, evading the immune system, propagating, avoiding cell death and so forth, are unique to that cancer.

• 1:45:28Speaker 00

  So if we understand the unique mutational landscape of that cancer, that gives us then an ability to say, again, in a world that isn't today's world, but hopefully not too long, far from now, where we have the ability to say, this combination of drugs is going to be effective at killing the cells in that tumor.

• 1:45:52Andrew D. Huberman?

  You're highlighting something really important that is both about the sociology of medicine and science. That is just, it's not disparaging of it. It's just, it is the way it is because of history.

• 1:46:01Speaker 00

  Yeah.

• 1:46:01Andrew D. Huberman?

  So much of the way things are in medicine and science can be answered by the, a phrase that everyone should hate, which is, well, we've always done it that way. Which is the worst reason to do anything unless it's working spectacularly well. Right? But is it a stretch to say that there are some liver cancers that are called liver cancer, but that are actually much closer in terms of their cellular phenotype to cancer of a cardiomyocyte because of the way that, say, MPC1 is changed? In other words, like, should we be classifying cancers as, oh, this is a cancer of the sort that the cells are making too much of themselves?

• 1:46:41Speaker 00

  Yeah.

• 1:46:41Andrew D. Huberman?

  As opposed to they're overusing energy? There's too much pyruvate. I'm making this up, right? I'm, obviously not my field, but rather than think only about address in the body.

• 1:46:51Speaker 00

  Yeah. No question that we should be thinking about the specific features of cancer. I've been talking about it in terms of the mutation, the specific mutations that define a cancer. And I think that's a useful way to do it because those mutations in a way are the instructions for making a new cell, right? The genome of a cell are the instructions for how to make a new cell, the constituents that would make up a new cell. But I think a very important feature that you're touching on that I appreciate you bringing up is on top of that, layered on top of that, is the unique metabolism that makes up that cell, right? That enables those instructions to be executed.

• 1:47:35Speaker 00

  You know, a cell can have all the right instructions to make a new cell. But if it doesn't have the building blocks, the lumber and the bricks and the mortar to make a new cell, it can't make a new cell. And so I think that's a really important feature of this that we need to talk about. And there's been a lot of energy in the, in the field over the last 10 or 15 years, maybe even 10 years or less, at trying to specifically block the resource allocation of cancer cells toward building new, new cells. The challenge there again is that it's fairly easy to develop resistance to that. A cancer cell can just make a mutation and rewire its metabolism to build that same thing a different way. But that is a very important feature of the cancer too.

• 1:48:20Speaker 00

  Beyond just the mutations are the, are the metabolic processes that enable those mutations to be manifest in, in, in what turns into a tumor.

• 1:48:31Andrew D. Huberman?

  How far are we from a world where I drink a fluid? And it's a safe fluid, because we do this for like other types of imaging. And I step into a tube and I do it when I'm like five and I do it when I'm 50. And I get a picture of red and green in every cell. Right? So I get like an image of like the proportion of my metabolism in different organs. And you could zoom in to a single cell. This is not like science fiction at the level, like it couldn't be done, where you say, okay, like this is a healthy cardiomyocyte and it's using 65% of its energy to just keep pumping. And then it like puts aside a little bit to make sure it can make more of its stuff so it stays around. A little bit, it's like going to this other pathway. And like, that's a healthy cardiomyocyte.

• 1:49:16Andrew D. Huberman?

  We know this from the population of, of age match data. And then when I'm, you know, 40, 50, you go, yeah, I don't know, like your heart's looking a little more green than red or something like that. We can kind of turn the dial back. Like, like we have druggable, you know, targets inside of cells and like, kind of like adjust the, the energy allocation. Like, is what I'm describing like so crazy? Because I can imagine a mouse experiment or paper would probably come out on that next week if it hasn't already. And like, that's kind of what you want. You want subcellular resolution.

• 1:49:48Speaker 00

  Yeah.

• 1:49:48Andrew D. Huberman?

  Because I feel like we've gone from this place where like, I was around in the first MRI, like functional magnetic. This imaging stuff was kind of like, here's a person looking at a banana. Here's a person hearing a joke. And like, now you can see dynamics and you can see axon pathways. But if we get down to the cells, cool. It's a lot of salt and pepper. Then you get down to the inner workings of the cells. You can't see everything. If you look at everything, it's going to look like chaos. Someone put on X this morning, actually, a AI rendering of all the proteins in a cell in one tiny patch of cell. And it's just like overwhelming. You're just like, oh my God, like there's so much here. But if you just say like, let's just look at metabolism at this keynote. And we know what healthy should be. Here's where you're at. And you're just trying to tilt that balance.

• 1:50:31Andrew D. Huberman?

  I mean, that to me feels like a, that could be done.

• 1:50:34Speaker 00

  Yeah.

• 1:50:35Andrew D. Huberman?

  Like, we've got smart people working on this. We need more money for scientists to work this stuff out and more scientists to do that work. But I feel like that's doable.

• 1:50:44Speaker 00

  Conceptually, pieces of that are doable. I think, you know, when you talk about, can we basically image metabolism with cellular resolution? I should be clear, that's a very difficult problem. The spatial resolution, the ability to see fine enough detail to make out individual cells are even smaller than that. That's a challenge. That's definitely a challenge inside a human body. And it's also a challenge to be able to have a surrogate of metabolism that we can actually see. Of course, our metabolism.

• 1:51:20Speaker 00

  There's nothing visual that we can see with the naked eye, right? There's nothing I can see in the metabolism of a cell. So what could we make that would enable us to visualize that? There's really exciting tools being developed of many different kinds to be able to image various features of metabolism in a cell.

• 1:51:38Andrew D. Huberman?

  Well, we would, in neuroscience, I mean, again, I was fortunate to be part of this wave of technology, didn't contribute to building any of it, but it was like, how do you know which brain areas are active? Well, you could drop electrodes in, or you could remove a piece and go, well, it probably did that when it was there because you lost that function. But, you know, a lot of it was just blood flow. It was like oxygenated to deoxygenated blood reflects light differently. And like you'd get these beautiful maps, but you were just looking at blood flow now. Then you got too deoxy glucose, you could look at glucose uptake, but it was spatially very crude, or it was the, the time resolution wasn't very good. I feel like we've come some way. You can look at voltage, you can look at calcium.

• 1:52:16Andrew D. Huberman?

  I feel like the moment that chemists, bioengineers and physicists and computers came into biology, things got a lot better.

• 1:52:26Speaker 00

  Yeah.

• 1:52:27Andrew D. Huberman?

  I mean, some people say it got a lot worse.

• 1:52:28Speaker 00

  Yeah.

• 1:52:29Andrew D. Huberman?

  But they retired now. So like it got a lot better because you could see what's really happening. Maybe I'm overly optimistic.

• 1:52:35Speaker 00

  Yeah, no, I, I think there, we need to be able to figure out what to measure. I mean, that's obviously a key thing. What would be the metabolic parameter? What would be the one metabolic parameter you'd really want to measure to assess? Is this cell healthy or not healthy? And it's hard to know exactly what that one thing would be, or a collection of things, and then figure out a way to measure that non-invasively, so to speak. You know, it's one thing if, if I'm going to measure that, do I have to cut off my arm, shave it into slices and, you know, measure it?

• 1:53:07Andrew D. Huberman?

  Nobody wants that.

• 1:53:09Speaker 00

  So how can I measure it without, you know, doing damage to me while I'm measuring it? These are hard problems, but as you say, the technology just keeps getting better in all versions of this. And the experimental tools, the tools that we can use in mice or in cells and culture are definitely getting better. And that, that's, that's an aspect of this field of, of studying metabolism that's really exciting is our ability to now be able to measure what's happening at individual places in individual cells and looking at specific individual molecules, you know, intermediates and products and substrates of these, this metabolic map. And that I think is teaching us a lot about how metabolism works in individual cells.

• 1:53:52Speaker 00

  And that is then going to be informative when we think about how it's working in a human.

• 1:53:57Andrew D. Huberman?

  I'm intrigued by this really wild thing that you see in the news every once in a while, which I believe to be true, but no one can explain, which is that there are dogs and there are occasionally people who can detect the scent of cancer beyond chance. Like this is like, no one really knows the basis of this. And recently there's an example, my understanding is it's validated, a woman who was able to smell Parkinson's as a musty scent, a musky, excuse me. And now spouses of people that had Parkinson's and particularly the female, the wives of these, like, oh yeah, I remember this. Now, of course, there's a whole lot of like placebo correlation, just so story that can emerge from that. But as you're telling me some of this, like, obviously you wouldn't want this to be the

• 1:54:41Andrew D. Huberman?

  one and only frontline detection system, but it kind of makes sense that if, if cellular metabolism is at the heart of certain cancers or neurodegenerative conditions, it makes sense that we're breathing out the byproducts. Obviously these scents are just correlated, right? And the shifts in, with infants, parents are remarkably good at being like, something's off because they can't communicate verbally with us yet, right? Like something's off in their stool or something is off in their skin pallor that's not extreme. And it become remarkably astute at detecting real underlying issues. So do you think that there could be useful information coming from the air we expel in terms of revealing at a systemic level, or maybe even at a cellular level, how well

• 1:55:24Andrew D. Huberman?

  or poorly we're regulating energy?

• 1:55:27Speaker 00

  Yeah, I mean, obviously, as you said, and you're, in alluding to this, this is again, at the frontier of science, and I don't think we understand much of the specifics. But I think you could imagine that because again, smells, scents are chemistry, right? These are chemical compounds that are coming from the person. And when a person's doing different metabolism, they're going to be producing different chemicals in different proportions. And I think it is possible that those can be detected in specific ways. That's not so dissimilar from some of the diagnostics that we do use where we actually measure the blood chemistry. You know, the blood chemistry is different between people that have different diseases and don't.

• 1:56:07Speaker 00

  And so, you know, and obviously the breath is some measure of the chemistry that's going on in the person. It's obviously different from the blood, but it's a fascinating topic. And, and as that gets to chemical specificity, it'll become probably more clear what's going on there and why. Why is Parkinson's specifically susceptible to that different chemistry in a way that can be detected by scent?

• 1:56:34Andrew D. Huberman?

  We were talking a few moments ago about excess energy toxicity. This is something that Dr. Lane Norton brought up on this podcast. He's a serious biochemist, nutrition, exercise, science guy, public educator, loves randomized control trials and meta-analyses. That's like his, if it's not there, he's not interested, or he's perfectly interested in tossing away everything else. So that's kind of his hallmark. So that should feel good to you and just knowing that. But he talks about this energy toxicity, you know, like excess calories leads to problems, not just because of the presence of excess body fat, but because of just too much energy at the front end creates downstream biochemical issues across the body. How does this relate to some of what we've been discussing?

• 1:57:18Speaker 00

  There's a widely accepted hypothesis that mitochondria with excess energy leads to problems. You know, many people that, that are listening have probably heard of reactive oxygen species. This is, you know, forms of oxygen that become reactive and end up spinning out and damaging proteins and nucleic acids. And I think it is, again, widely accepted, not universally, but widely accepted that one of the contributors to that is mitochondria that have too much energy. Basically the form that energy takes when it's extracted from the food we eat and before it's converted to ATP is powering the mitochondria.

• 1:58:02Speaker 00

  And when that mitochondria is overpowered, that leads to a state that is very susceptible to generation of these reactive species that end up damaging our genome, creating mutations and damaging proteins and creating many of the problems that we see. And I think there's been a number of studies that have suggested they might contribute to various pathologies, including aging. So I think that idea of excess energy is one that is really important to consider from the level of the organism down to the level of individual cells and even the mitochondria within those cells.

• 1:58:36Andrew D. Huberman?

  Once again, I'm thinking about the notion like no individual or collection of individuals or cell or collection of cells can really get away with, or what's the saying, like you pay the piper somehow. Like cells really get punished for cheating themselves by taking too much energy or not allocating it correctly. Like you can level up from this like single cell analysis all the way to, to societies, I actually think. This is fascinating for a variety of reasons. First of all, again, we've never had a serious discussion about what mitochondria actually do besides just create, help create energy. So first of all, thank you so much for telling us how they actually allocate their resources

• 1:59:19Andrew D. Huberman?

  towards things other than just making more energy for usage to build more of oneself. Also for framing that in the context of, of disease and health. And also for shining a light on the fact that like, while we might be right here now, that I do think, I'll just say what maybe you were trying to say, but are too humble to say, that I think as long as we're looking at things just like, oh, this is a cancer of this tissue and not actually asking what specifically is happening to the cells there that might be common to other cancers elsewhere. And like changing our nomenclature and boundaries of how we classify things, opening up our minds to it, as well as really thinking about the whole body as a, like a constellation of these little micro factories that is us.

• 2:00:04Andrew D. Huberman?

  I am certain that people hearing this will no longer think about like metabolism just as them, my metabolism, but this constellation of metabolisms and, and the health status of, of all the different cells. So it goes without saying that it's a really unique opportunity for the general public to hear from like a world-class biologist working on these specific issues and related issues for decades now, right? And so, and you're a very busy person. So I'm very grateful to, to you, to the University of Utah for allowing and encouraging public education to Howard Hughes. No, they didn't tell me to say this, but I think people really need to understand what an amazing opportunity is to learn from people. And there are others in the field, you're so good at attribution, who are, who are

• 2:00:46Andrew D. Huberman?

  really trying to figure out these really hard problems in biology that are crucial to health and to disease, and therefore to curing disease, and really trying to move things forward in your workshop that you call a laboratory. So you don't have to do this sort of thing, but I greatly appreciate it. And I speak on behalf of many, many people really appreciate it. There's information and then there's superb information. So thank you so much.

• 2:01:08Speaker 00

  Thanks, Andrew. It's been a lot of fun.

• 2:01:09Andrew D. Huberman?

  We'll do it again.

• 2:01:10Speaker 00

  Anytime.

• 2:01:11Andrew D. Huberman?

  Cheers.

• 2:01:11Speaker 00

  Thank you.

• 2:01:12Andrew D. Huberman?

  Thank you for joining me for today's discussion with Dr. Jared Rutter. To learn more about his work, please see the links in the show note caption. If you're learning from and or enjoying this podcast, please subscribe to our YouTube channel. That's a terrific zero cost way to support us. In addition, please follow the podcast by clicking the follow button on both Spotify and Apple. And on both Spotify and Apple, you can leave us up to a five-star review. And you can now leave us comments at both Spotify and Apple. Please also check out the sponsors mentioned at the beginning and throughout today's episode. That's the best way to support this podcast. If you have questions for me or comments about the podcasts, or guests or topics that you'd like me to consider for the Huberman Lab podcast, please put those in the comments section on YouTube. I do read all the comments. For those of you that haven't heard, I have a new book coming out.

• 2:01:56Andrew D. Huberman?

  It's my very first book. It's entitled Protocols: An Operating Manual for the Human Body. This is a book that I've been working on for more than five years, and that's based on more than 30 years of research and experience. And it covers protocols for everything from sleep to exercise to stress control, protocols related to focus and motivation. And of course, I provide the scientific substantiation for the protocols that are included. The book is now available by pre-sale at protocolsbook.com. There you can find links to various vendors, you can pick the one that you like best. Again, the book is called Protocols: An Operating Manual for the Human Body. And if you're not already following me on social media, I am Huberman Lab on all social media platforms.

• 2:02:39Andrew D. Huberman?

  So that's Instagram, X, Threads, Facebook and LinkedIn. And on all those platforms, I discuss science and science-related tools, some of which overlaps with the content of the Huberman Lab podcast, but much of which is distinct from the information on the Huberman Lab podcast. Again, it's Huberman Lab on all social media platforms. And if you haven't already subscribed to our neural network newsletter, the neural network newsletter is a zero cost monthly newsletter that includes podcast summaries as well as what we call protocols in the form of one to three-page PDFs that cover everything from how to optimize your sleep, how to optimize dopamine, deliberate cold exposure. We have a foundational fitness protocol that covers cardiovascular training and resistance training. All of that is available completely zero cost. You simply go to hubermanlab.com, go to the menu tab in the top right corner, scroll

• 2:03:24Andrew D. Huberman?

  down to newsletter and enter your email. And I should emphasize that we do not share your email with anybody. Thank you once again for joining me for today's discussion with Dr. Jared Rutter. And last, but certainly not least, thank you for your interest in science.